Family of large biological molecules
POPULARITY
Categories
112 episodes with RNA
67 episodes with RNA
76 episodes with RNA
31 episodes with RNA
44 episodes with RNA
34 episodes with RNA
33 episodes with RNA
142 episodes with RNA
27 episodes with RNA
47 episodes with RNA
21 episodes with RNA
16 episodes with RNA
15 episodes with RNA
20 episodes with RNA
25 episodes with RNA
12 episodes with RNA
12 episodes with RNA
10 episodes with RNA
11 episodes with RNA
36 episodes with RNA
13 episodes with RNA
9 episodes with RNA
7 episodes with RNA
16 episodes with RNA
11 episodes with RNA
6 episodes with RNA
13 episodes with RNA
7 episodes with RNA
16 episodes with RNA
8 episodes with RNA
7 episodes with RNA
9 episodes with RNA
11 episodes with RNA
15 episodes with RNA
11 episodes with RNA
7 episodes with RNA
10 episodes with RNA
13 episodes with RNA
6 episodes with RNA
28 episodes with RNA
8 episodes with RNA
12 episodes with RNA
12 episodes with RNA
8 episodes with RNA
16 episodes with RNA
6 episodes with RNA
14 episodes with RNA
18 episodes with RNA
9 episodes with RNA
13 episodes with RNA
12 episodes with RNA
162 episodes with RNA
7 episodes with RNA
5 episodes with RNA
4 episodes with RNA
7 episodes with RNA
12 episodes with RNA
150 episodes with RNA
11 episodes with RNA
5 episodes with RNA
5 episodes with RNA
14 episodes with RNA
7 episodes with RNA
8 episodes with RNA
16 episodes with RNA
4 episodes with RNA
6 episodes with RNA
7 episodes with RNA
6 episodes with RNA
4 episodes with RNA
7 episodes with RNA
9 episodes with RNA
8 episodes with RNA
5 episodes with RNA
12 episodes with RNA
3 episodes with RNA
4 episodes with RNA
3 episodes with RNA
10 episodes with RNA
15 episodes with RNA
7 episodes with RNA
5 episodes with RNA
4 episodes with RNA
7 episodes with RNA
6 episodes with RNA
3 episodes with RNA
7 episodes with RNA
6 episodes with RNA
3 episodes with RNA
12 episodes with RNA
11 episodes with RNA
8 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
6 episodes with RNA
5 episodes with RNA
6 episodes with RNA
19 episodes with RNA
4 episodes with RNA
4 episodes with RNA
14 episodes with RNA
3 episodes with RNA
5 episodes with RNA
7 episodes with RNA
4 episodes with RNA
6 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
4 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
5 episodes with RNA
5 episodes with RNA
4 episodes with RNA
6 episodes with RNA
5 episodes with RNA
5 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
7 episodes with RNA
4 episodes with RNA
3 episodes with RNA
12 episodes with RNA
8 episodes with RNA
6 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
5 episodes with RNA
7 episodes with RNA
2 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
7 episodes with RNA
7 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
4 episodes with RNA
8 episodes with RNA
3 episodes with RNA
3 episodes with RNA
4 episodes with RNA
2 episodes with RNA
3 episodes with RNA
2 episodes with RNA
4 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
2 episodes with RNA
3 episodes with RNA
3 episodes with RNA
5 episodes with RNA
5 episodes with RNA
3 episodes with RNA
2 episodes with RNA
2 episodes with RNA
3 episodes with RNA
2 episodes with RNA
9 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
2 episodes with RNA
6 episodes with RNA
3 episodes with RNA
6 episodes with RNA
3 episodes with RNA
2 episodes with RNA
2 episodes with RNA
De Darwin a Santa: física sin cuentos (dos soles, origen de la vida y 727 km/s)Capítulos (YouTube)00:00 – Intro: ¿hay algo después de la muerte? Ciencia vs fe10:48 – Darwin: viaje, fósiles, Galápagos y selección natural16:39 – Copérnico y Galileo: del geocentrismo al Sol (lunas de Júpiter)20:14 – Kepler, elipses y la ciencia bajo la Inquisición + miedo a lo desconocido29:20 – ¿Cómo pudo surgir la vida? Experimento Miller-Urey y el rol del RNA35:21 – ¿Santa es físicamente posible? La cuenta: ~727 km/s y velocidad de escape42:34 – Dos soles como Tatooine: estrellas binarias, noches “infinitas” y multiversos mal entendidos50:22 – Cierre y dónde seguir a Daniel (Notas Astronómicas)DescripciónVolvió Daniel Isaac (Notas Astronómicas) para aterrizar temas que suelen asustar… con física. Hablamos de la idea de “nada” después de la muerte, por qué la ciencia no compite con la espiritualidad (pero sí exige evidencias), y nos vamos de tour histórico con Darwin, Copérnico, Galileo y Kepler: cómo pasamos del “todo gira a la Tierra” a entender órbitas elípticas y la evolución por selección natural.Luego bajamos a lo práctico:Origen de la vida: qué demostró realmente Miller-Urey y por qué el RNA importa.Santa Claus con física: si tuviera que repartir en ~36 h a ~100M de casas, ¡necesitaría ~727 km/s! (sí, más allá de la velocidad de escape
On today's ID the Future, host Casey Luskin continues a deep dive into the mounting hurdles facing origin of life (OOL) research with prebiotic synthesis expert Dr. Edward Peltzer. Peltzer, a seasoned ocean chemist and researcher, breaks down the critical flaws in the RNA world hypothesis, revealing that many successful lab experiments actually rely on investigator interference—intelligently designed interventions that researchers must make in experiments in order to yield results. But that's not how the prebiotic atmosphere would have worked, notes Peltzer: "Unless you've got graduate students and post-docs working on the early Earth to set up these conditions that were used in the experiments, it's not gonna happen." Peltzer also discusses how the goalposts of origin-of-life theory keep moving as our understanding of cellular complexity expands. And he shares a personal story of censorship as the discussion ends by exploring the risks faced by scientists who question the standard evolutionary paradigm. This is Part 2 of a two-part conversation. Look for Part 1 in a separate episode. Source
Molecular Therapy Editor-in-Chief Dr. Joseph Glorioso joins researchers Kathy Steece-Collier (Michigan State University), Jeffrey Kordower (Arizona State University), and Fredric Manfredsson (Barrow Neurological Institute) to discuss their groundbreaking work on RNA interference for Parkinson’s disease. This episode focuses on their recent article titled "Disease-modifying, multidimensional efficacy of putaminal CaV1.3-shRNA gene therapy in aged parkinsonism male and female macaques." Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.
Kimchi, a traditional Korean fermented vegetable dish, is rich in diverse lactic acid bacteria, bioactive compounds, and fibers that support gut integrity, microbial balance, immune signaling, and overall metabolic resilience A recent study published in npj Science of Food used single-cell RNA sequencing to map how daily kimchi intake influences immune cells, offering insight into food-driven changes in human immune regulation Their findings showed that kimchi strengthened key immune functions by helping cells recognize threats more effectively and supporting balanced T cell activity, without triggering overactive immune responses Beyond immune modulation, kimchi intake supports metabolic health, reduces body fat, improves cholesterol markers, nourishes the gut microbiome, strengthens the gut barrier, enhances digestion, and influences mood through gut-brain signaling Choosing raw, unpasteurized kimchi made with simple ingredients ensures you get the full benefit of its live cultures; homemade versions offer more control and better microbial diversity
We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China's growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Welcome to The Times of Israel's Daily Briefing, your 20-minute audio update on what's happening in Israel, the Middle East and the Jewish world. Diaspora affairs reporter Zev Stub and reporter Diana Bletter join host Jessica Steinberg for today's episode. As Spain implements the largest state-level boycott of Israel, Stub reviews elements of the embargo and whether it could set a precedent of similar gestures from other countries. Bletter reports on a recent visit to the northern city of Kiryat Shmona, badly damaged during the year of Hezbollah strikes, and still struggling to revitalize itself. A look at Israel's population numbers shows that more people exited the country in 2024 than entered it, reports Stub. This came even as statistics paint a nuanced picture of rising immigration to the country amid skyrocketing antisemitism globally. Finally, Bletter reports on the resilience and diversity of Israeli science and medical research, including research on coral reefs, and how cancer can help heal ailing hearts. Check out The Times of Israel's ongoing liveblog for more updates. For further reading: With new trade restrictions, Spain looks to trigger EU cascade against Israel Spanish Jews warn map of local Jewish and ‘Zionist’ businesses will lead to violence Half-empty and scarred by war, Kiryat Shmona sees protests – and grassroots rejuvenation More than 69,000 Israelis left Israel in 2025, as population reached 10.18 million In surprising breakthrough, scientists in Israel find cancer may help heal the failing heart Israeli scientists say tiny organisms can revamp their own RNA to survive extreme heat New Israeli research shows coral reefs shape the ebb and flow of local microbial life Subscribe to The Times of Israel Daily Briefing on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. This episode was produced by Podwaves. IMAGE: A pro-Palestinian demonstrator holds a banner reading: 'Boycott Israeli apartheid' during a protest in Madrid, Spain, Saturday, Oct. 4, 2025. (Bernat Armangue/AP Photo)See omnystudio.com/listener for privacy information.
Are you tired of praying for healing while your body, mind, and diagnosis stay the same? In this Prophetic Spiritual Warfare message, Kathy DeGraw calls you out of passivity and into kingdom dominion, speaking directly to your DNA in the power of Jesus. Purchase Kathy's book Healed at Last – Overcome Sickness to Receive your Physical Healing on Amazon https://a.co/d/6a6mt8w or at: https://www.kathydegrawministries.org/healed-at-last/ Purchase Anointing Oil with a prayer cloth that Kathy has personally mixed and prayed over on Kathy's Website or Amazon. Order anointing oil by Kathy on Amazon look for her brand here https://amzn.to/3PC6l3R or Kathy DeGraw Ministries https://www.kathydegrawministries.org/product-category/oils/ Training, Mentorship and Deliverance! Personal coaching, deliverance, ecourses, training for ministry, and mentorships! https://www.kathydegrawministries.org/training/# So many believers are begging God for healing while tolerating sickness, settling for prescriptions, and forgetting the dominion Jesus already gave them. In this fiery message, Kathy DeGraw exposes passivity, calls you higher, and teaches you how to speak to your DNA, and cells in the name of Jesus. From Pentecostal altar-fire to practical teaching, Kathy shows you how to stop chasing everyone else's prayers and start using your own God-given authority. You'll learn why dominion is more than occasionally "taking authority" over a symptom—it's a lifestyle that shifts spiritual atmospheres, silences demonic assignments, and commands sickness to bow. Kathy shares testimonies of being healed 17 times without medical intervention, how she prays over DNA, RNA, proteins, and prions, and why anointing oil is a powerful point of contact when it's used by faith. If you're battling chronic illness, neurological issues, or fear of disease, this episode will provoke you to get hungry, get aggressive, and go to the throne room yourself until you walk in divine health and fulfill your destiny. #divinehealing #spiritualwarfare #deliveranceministry #anointingoil #walkindominion **Connect with Us** - Website: https://www.kathydegrawministries.org/ - Facebook: https://www.facebook.com/kathydegraw/ - Instagram: https://www.instagram.com/kathydegraw/ Podcast - Subscribe to our YouTube channel and listen to Kathy's Podcast called Prophetic Spiritual Warfare, or on Spotify at https://open.spotify.com/show/3mYPPkP28xqcTzdeoucJZu or Apple podcasts at https://podcasts.apple.com/us/podcast/prophetic-spiritual-warfare/id1474710499 **Recommended Resources:** - Receive a free prayer pdf on Warfare Prayer Declarations at https://kathydegrawministries.org/declarations-download - Kathy's training, mentoring and ecourses on Spiritual Warfare, Deliverance and the Prophetic: https://training.kathydegrawministries.org/ - Healed At Last ~ Overcome Sickness and Receive your Physical Healing: https://www.kathydegrawministries.org/healed-at-last/ - Mind Battles – Root Out Mental Triggers to Release Peace!: https://www.kathydegrawministries.org/product/mind-battles-pre-order-available-january-2023/ -Kathy has several books available on Amazon or kathydegrawministries.org **Support Kathy DeGraw Ministries:** - Give a one-time love offering or consider partnering with us for $15, $35, $75 or any amount! Every dollar helps us help others! - Website: https://www.kathydegrawministries.org/donate/ - CashApp $KDMGLORY - Venmo @KD-Ministries - Paypal.me/KDeGrawMinistries or donate to email admin@degrawministries.org - Mail a check to: Kathy DeGraw Ministries ~ PO Box 65 ~ Grandville MI 49468
In the season one finale, Manousos and Carol do the most expected thing in their first in-person meeting: hate each other. The hive is dong an effective job keeping Carol busy, as they find new ways to propagate the RNA into the remaining 12. Manousos proves to be an agent of chaos, with a purpose and is not understanding why Carol is choosing the girl over the world. If you started watching The Upon Further Review via Pluribus, let us know in the comments, because we are happy to have you kick it with us!Please! Subscribe where we are, especially here on YouTube
America Out Loud PULSE with Dr. Peter McCullough and Malcolm Out Loud – Is Dr McCullough aware of increased levels of Alpha-Gal Syndrome? I have one concern regarding curcumin. I heard from a doctor that curcumin inhibits natural RNase L, an enzyme that degrades RNA, including exogenous mRNA. Could you enlighten me on that, as surely we'd want to speed that process?
America Out Loud PULSE with Dr. Peter McCullough and Malcolm Out Loud – Is Dr McCullough aware of increased levels of Alpha-Gal Syndrome? I have one concern regarding curcumin. I heard from a doctor that curcumin inhibits natural RNase L, an enzyme that degrades RNA, including exogenous mRNA. Could you enlighten me on that, as surely we'd want to speed that process?
In this Mol Bio Minutes mini-episode, Laurynas Alijošius shares how Rolling Circle Amplification (RCA) provides a reliable, high-yield approach for amplifying circular DNA prior to next-generation sequencing (NGS). This isothermal method avoids the need for thermal cycling and even bypasses the need for specific primers—making it ideal for challenging viral genomes, rare targets, or field samples.Powered by the strand-displacing phi29 DNA polymerase, RCA amplifies DNA with impressive sensitivity and minimal GC bias. Laurynas breaks down the steps of multiple displacement amplification (MDA), explains why exonuclease-resistant primers are important, and explores how engineered polymerases like EquiPhi29™ DNA Polymerase dramatically improve yield and reduce reaction times. RCA products can be cleaned up and debranched to support a range of downstream workflows, including nanopore sequencing and transcriptomics.From single-cell genomics to phage-based applications and in vitro expression systems, RCA is more than just a pre-NGS step; it's a versatile tool with broad utility. Whether you're stabilizing viral RNA or tackling ultra-low-input samples, RCA and whole genome amplification offer new flexibility for today's demanding sequencing workflows. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Send us a textSubscribe and unleash your inner science goblin. We see you. We respect it.DNA isn't magic—but it is one of the most powerful instruction systems in the universe.In this deep-dive episode of Wildly Curious, Katy Reiss and Laura Fawks Lapole break down genetics, DNA, and inheritance in a way that actually makes sense—no lab coat required. From the tiny molecular code inside your cells to the ethical questions surrounding modern gene editing, this episode connects the science to real life.
BUFFALO, NY — December 23, 2025 — A new #research paper was #published in Volume 17, Issue 11 of Aging-US on November 25, 2025, titled “A natural language processing–driven map of the aging research landscape.” In this study, Jose Perez-Maletzki from Universidad Europea de Valencia and Universitat de València, together with Jorge Sanz-Ros from Stanford University School of Medicine, used artificial intelligence (AI) to analyze a century of global aging research, revealing shifts in focus and highlighting underexplored areas. The team analyzed over 460,000 scientific abstracts published between 1925 and 2023 to identify key themes, trends, and research gaps in the study of aging. Their goal was to provide a comprehensive, unbiased view of how the field has evolved and where future research could have the greatest impact. The study found that aging research has moved from basic cellular studies and animal models to a growing focus on clinical topics, particularly age-related diseases such as Alzheimer's and dementia. Using natural language processing and machine learning, the researchers grouped publications into thematic clusters and tracked how interest in each topic changed over time. “By integrating Latent Dirichlet Allocation (LDA), term frequency-inverse document frequency (TF-IDF) analysis, dimensionality reduction and clustering, we delineate a comprehensive thematic landscape of aging research.” One key finding was the growing separation between basic biological studies and clinical research. While both areas have grown significantly, they often progress independently with limited overlap. Clinical studies tend to focus on geriatrics, healthcare, and neurodegenerative diseases, while basic science emphasizes cellular mechanisms such as oxidative stress, telomere shortening, mitochondrial dysfunction, and senescence. The authors note that this lack of integration limits the translation of laboratory discoveries into medical applications. The study also showed that some emerging topics, such as autophagy, RNA biology, and nutrient sensing, are expanding rapidly but remain separated from clinical applications. In contrast, long-established links, such as those between cancer and aging, remain strong. The analysis also highlighted that potentially important associations, such as those between mitochondrial dysfunction and senescence or epigenetics and autophagy, are rarely studied and may be new research opportunities. This AI-driven analysis offers a new way to guide future research by identifying how different areas of aging science are interconnected or isolated. It also highlights how research priorities may be shaped by policy or funding trends, as seen in the heavy focus on Alzheimer's disease. As the global population continues to age, understanding how biological processes relate to clinical outcomes is critical. This study not only offers a historical map of aging science but also serves as a tool to support more connected, interdisciplinary, and effective future research. DOI - https://doi.org/10.18632/aging.206340 Corresponding author - Jorge Sanz-Ros - jsanzros@stanford.edu Abstract video - https://www.youtube.com/watch?v=O4dJUGQ2ZcU Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, visit https://www.Aging-US.com and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Drs. Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at the MDA 2025 conference in Dallas, Texas, in March 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established in contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The ASPIRO clinical trial is on clinical hold since September 2021. In this part, Dr. Beggs will provide an introduction to gene-directed therapies.Alan Beggs, PhDI'm going to talk now about challenges, a little bit of background in the history and the development of AAV-mediated gene therapies, in particular for neuromuscular disorders. There are a lot of aspects about neuromuscular disease that make it a good group of conditions to target by gene replacement therapies. These are traditionally single gene disorders with known identified oftentimes protein deficiencies, so null mutations leading to lack of a protein.The primary tissue, the therapeutic target is a skeletal muscle, and so we can target that with the appropriate viral vectors. There's a major unmet medical need and substantial clinical burden for these conditions. As rare diseases, they place a very substantial burden on both health systems and patients, both economically and in terms of personal difficulties.I like to think about gene therapy, which is generically used for one category of this, to really think about gene-directed therapy. So this would be any therapy directed at the nucleic acids that are either encoding our DNA or are encoding the messenger RNA transcripts. So one approach to a gene-directed therapy can be directed at the RNA level. I think you're all familiar with the Exon-skipping approaches that target mRNA splicing.There are other methods for either knocking down toxic gain of function messenger RNAs, and there are methods now being developed to edit messenger RNAs. So this represents one class of gene therapy. You can also approach gene therapy at level of DNA by editing or changing the DNA in situ. So various CRISPR-Cas9-based approaches. There's now prime editing and other approaches for genetic engineering that target specific locations, often using bacteria endonucleasis that target with oligenucleotides that target specific sites.And then finally, there's gene replacement therapy, which is what we're going to spend most of our time on today, which really aims to not take away what's there and replace it, but to replace the missing protein product by providing a copy of the healthy or the complete wild type gene. Often, it can either be integrated into the chromosomes or remain extrachromosomal.So whether or not that happens really depends on the type of vector or approach you use. You can see here a number of different approaches for transferring in a therapeutic gene. The two most commonly used in clinical trials are lentivirus and AAV, and they have different strengths and weaknesses. Lentiviruses are used frequently for hematologic diseases.Lentivirus is a member of the retrovirus family and has the characteristic that it actually integrates into the DNA. So lentiviral treatments tend to be long-acting. However, they also suffer from the risk that by integrating into the DNA, you might have site-directed mutagenesis. And there have been known instances of cancers that arose through integration at the wrong site.In the next part, Dr. Beggs will cover the history and challenges in the development of AAV-mediated gene therapies.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show
Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Doctors Roberts and Longo will discuss treatment with gene therapies.Question: Can one administer AAV-mediated gene therapy repeatedly?Mark Roberts, MDI think the traditional view would have been no. One can think of gene therapy as a silver bullet. Hopefully, it will reach its target. But if it's not effective, that bullet has been shot, the immunological response has occurred, and it means redosing, at least with that particular vector, may become difficult. But this situation is changing and evolving as we have better understanding of immunological modulation for repeat testing. We were discussing this yesterday evening, weren't we, Professor Longo?Nicola Longo MD, PhDCorrect. Basically, the current AAV-based gene therapy cannot be readministered. It is either effective, or it doesn't work. The other thing is that even though in theory, one could utilize a different AAV vector with different immunogenicity, there is many times cross-reactivity among the different adenovirus, adeno-associated viruses. Now, there are approaches in animal models in which you give a strong immune suppression to prevent the creation of the immune response against the adeno-associated virus, and at least in the animal model, it has been possible to give some of the gene therapy repeatedly.The second approach that is being tested is with gene correction therapy, in which by using an RNA guide and the CRISPR/Cas9 system delivered by lipid nanoparticles, you basically correct some of the effective genetic information. Obviously, since this is done by lipid nanoparticles and not by an AAV, the immunity that you create is really not there. You can give this one repeatedly, and in theory, it can be given more than one time. But again, you are absolutely correct. The current gene therapy cannot be given twice, and either it works or it doesn't work.Question:vWill gene-therapy-treated patients be able to go back to the standard of care or enzyme replacement therapy?Mark Roberts, MDI think when we're talking to patients about the potential benefits of gene therapy and the amelioration of the requirement to have these infusions on a regular basis of ERT, the hope is that will work, but they need to be reassured that we can potentially go back to the ERT. Gene therapy is an important treatment, but we don't know the destination of the patient at the beginning, and we have to make it available to them to go back to ERT.One of the crucial questions, of course, though, is the basis of the immunological reaction that perhaps prevented the gene therapy being effective. If it's against the viral vector, well, okay. If it's against the transgene, not great. If it's against the functional protein, that becomes more difficult. It is somewhat, I think at this time, to be fair to say to patients, think of gene therapy as a trial treatment. It is somewhat a leap of faith and an important observation, of course, for the patient community, but just be aware there may be downsides.Nicola Longo MD, PhDThey totally agree with Dr. Roberts. In general, they should be able to go back to enzyme replacement therapy if the gene therapy is not effective. However, what we are starting to appreciate is that we need to understand the immune response, not just to the enzyme replacement therapy, but also to gene therapy. What this field is doing is forcing geneticists to deal with the immune response. I feel that historically has not been dealt together. The two things need to be integrated. The advantage of the gene therapy is that the protein is produced endogenously. There should be the development of some degree of tolerance with time in the body towards the endogenous continuous production of a protein.Now, will that happen all the time? I still do not know. Again, we need to understand much better what is the integration of the immune system with the response to gene therapy in the ongoing clinical trials.
Nicola Longo MD, PhD, and Mark Roberts, MD Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice.The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss vectors, different strategies, modes of administration and targets in gene replacement therapies.Mark Roberts, MDNow in the broader sense, gene replacement therapy seeks to actually deliver genetic material directly into the host cell to influence gene expression. In the most simple idea, one of course has a vector, this is most commonly but not exclusively a virus, which can then be given intravenously for example, and can hope to potentially correct the condition within the individual cells using novel transgenes. Suitable candidate conditions for this as examples of genetic conditions are now well understood. And crucially, this applies not only towards some more recessive, but dominant and even accident conditions.Across the piece, one can see for example, mitochondrial problems, spinal muscular atrophy as is well known, X-linked myotubular myopathy, Duchenne muscular dystrophy, a very common condition affecting one in 3000 male individuals, Pompe disease of course, an important focus of the meeting here, but other very common conditions, for example, cystic fibrosis, immunological conditions and perhaps obviously very crucial in early work on gene therapy, hemophilia.Let's now think about the approaches to gene therapy. One can seek to work at the DNA level and gene replacement. In essence, one is trying to put a new transgene through into the nucleus that will ultimately be transcribed and translated and produce the important functional protein that is lost. Gene editing which is a very exciting new technology or CRISPR technology actually seeks to actually modify in vivo the actual mutations that are responsible for the pathogenic production of abnormal proteins and correcting these and actually producing a more normalized protein.But of course there are also RNA approaches where one seeks to actually repair the mRNA transcripts copied from the mutated gene. For example, this may be a novel approach that could be extremely useful in myotonic dystrophy, a multisystem condition. When we talk about the viral vectors, predominantly we're talking about viruses. Those such as adenoviruses and AAV viruses which have the virtue of not integrating into the host genome or at least not in a large amount, and those which deliberately seek to integrate into host genome such as retroviral or lentiviral systems that may be particularly useful for ex vivo systems.There are of course other ways to get genetic payloads into the nucleus, various polymers, nanoparticles and even cell penetrating peptides. Nanoparticles in particular is certainly on the ascendant. That being said, in a recent review of the clinical trials in gene therapy, it was certainly the viral vectors that stood out both in direct gene replacement with lentivirus and AAV, but also actually as delivery systems, for example, for gene editing. An example of what one is seeking to do with AAV, so of course one seeking to remove the native DNA, insert the new transgene directly into the vector and of course keen to make sure that there's a high transmission into the capsid producing a recombinant AAV, which then can be given as a treatment and hopefully produce a therapeutic increase in the functional protein that is deficit in the disorder.In the next part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.
Nature: Asteroids, antibiotics and ants: a year of remarkable scienceIn this episode:1:58 Evidence of ancient brine on an asteroidSamples taken from the asteroid Bennu by NASA's OSIRIS-REx spacecraft suggest the parent body it originated from is likely to have contained salty, subsurface water. This finding provides insights into the chemistry of the early Solar System, and suggests that brines might have been an important place where pre-biotic molecules were formed.News & Views: Asteroid Bennu contains salts from ancient brineNature Podcast: Asteroid Bennu contains building blocks of life08:01 How gene expression doesn't always reflect a cell's functionCells are often grouped into categories according to the RNA molecules they produce. However a study of zebrafish (Danio rerio) brains revealed that cells can be functionally diverse even if they appear molecularly similar. This finding adds more nuance to how a cell's ‘type' is ultimately defined.News & Views: Does a cell's gene expression always reflect its function?12:01 The disproportionate mortality risks of extreme rainfallAn assessment of death rates in India's coastal megacity of Mumbai revealed that the impact of extreme rainfall events will be highest for women, young children and residents of informal settlements. This situation is likely to become more pronounced as a result of climate change.News & Views: Extreme rainfall poses the biggest risk to Mumbai's most vulnerable people14:46 An AI-designed underwater glueInspired by animals like barnacles and aided by machine learning, researchers have developed a super-sticky compound that works as an underwater adhesive. To demonstrate its properties, researchers applied it to a rubber duck, which stuck firmly to a rock on a beach despite being battered by the sea.News & Views: AI learns from nature to design super-adhesive gels that work underwaterNature Podcast: Underwater glue shows its sticking power in rubber duck test Hosted on Acast. See acast.com/privacy for more information.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show
Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Fei Li Kuang, MD, PhD, an allergist and immunologist, at Northwestern Medicine, about receiving two APFED HOPE on the Horizon Grants. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own. Key Takeaways: [:50] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz. [1:14] Holly introduces today's topic, two APFED HOPE on the Horizon Pilot Grant Projects and today's guest, Fei Li Kuang, MD, PhD, an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, Illinois. [1:42] Dr. Kuang is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples. Holly thanks Dr. Kuang for joining us. [2:05] As a child, Dr. Kuang always wanted to be a scientist. She is so grateful to live out her childhood dream, and it's because of the amazing people who have supported her, most importantly, her parents. [2:29] In graduate school, Dr. Kuang studied B cells. When she went on to do an allergy fellowship, she thought she would study B cells and care for patients with B cell problems. Instead, she fell in love with allergy and eosinophilic disorders. [2:50] Dr. Kuang is here, in part, because of the different mentors she has had, and in large part, because of the patients she has met along the way. [3:20] Dr. Kuang had the opportunity to work with Amy Klion at the NIH in a clinical trial to treat patients with a drug that gets rid of eosinophils. She says it was a dream come true after her training. [4:02] She says she learned so much about eosinophils, their unusual biology, and the mystery behind what they are here for. She got hooked. [4:15] Dr. Kuang thinks the patients you meet in a clinical trial in a special place like NIH occupy a space in your heart that makes you want to keep working on the subject area. [4:34] Patients in a clinical trial have given up a bunch of their time to travel to Bethesda, Maryland. For the trial Dr. Kuang participated in as a Fellow, it was a good year of their time to come out and do it. [4:47] Dr. Kuang felt there were so many interesting questions, from an intellectual point of view, but there was also a real need from patients with chronic conditions. It was a beautiful opportunity to marry scientists with physicians in training. [5:36] Dr. Kuang shares some knowledge about eosinophils. They are white blood cells that are in all of us. They have little pink packages or granules that "jumped out" in the light microscope almost 200 years ago, when we first identified them. [6:00] Dr. Kuang says that animals, dating back to reptiles, and different species of dolphins, all have eosinophils. A veterinary scientist, Dr. Nicole Stacy of the University of Florida, has taken photos of eosinophils from all these different species. [6:21] They've been around for a long time. What are they good for? What we know is that they are associated with disease conditions, such as asthma and others, including leukemia. Those were the classic first studies of eosinophils. [6:42] Now, we have a different mindset about eosinophils from work by the late James Lee at Mayo Clinic, Arizona. [6:58] Dr. Kuang credits Dr. Lee with suggesting that eosinophils not just cause us problems but also help treat parasitic infections, maintain tissue homeostasis, help wound healing, and tissue repair. That's a new area we are beginning to appreciate. [7:41] Dr. Kuang says we need to be open-minded that in some circumstances, eosinophils may be helpful or innocent. Now we have tools to start to understand some of that. We need to collect information from patients being treated with medicines. [8:10] Ryan tells of being diagnosed as a kid. Doctors explained to him that eosinophils fight parasites, but in some people, they get confused and attack the esophagus. That's EoE. That was easy to understand, but he knew that the researchers knew more. [8:53] Ryan is grateful to the patient population around eosinophilic esophagitis, and is proud of APFED's support of patients and caregivers with HOPE Grants. APFED has the HOPE on the Horizon Research Program, entirely funded by community donations. [9:13] To date, APFED has directed more than $2 million toward eosinophilic disease research initiatives through various grant programs. As a patient advocacy organization, APFED works with fantastic researchers who submit innovative research ideas. [9:32] These research ideas go through an extensive and competitive peer-review process, supported by researchers and clinicians in the APFED community. [9:42] Today, we're going to discuss two different projects supported by HOPE Pilot Grants with Dr. Kuang. [10:00] Dr. Kuang thinks there are two ways these grant programs are important to patients. One is advancing research by nurturing seedling investigators. Dr. Kuang got her first grant when she was a Fellow. It was an incredible opportunity. [10:25] These grant programs also nurture seedling ideas that don't have enough evidence yet to garner the larger NIH grants, and so forth. There are other sources for grants: pharmaceutical companies. The grant programs are for seeds. [10:49] Patients need to know that there are new things that are given some chance of being tested out. Research takes some time, and the FDA process of getting a drug approved is long. [11:04] For the newly diagnosed patient, it can feel overwhelming. It feels like there's a loss of control. Sometimes, participating in something like APFED, being part of a community, gives back a sense of control that is lost when you're handed a diagnosis. [11:45] For patients who have had it for a long time, when they participate in research and become engaged in organizations like APFED, they know they may not directly benefit today, they may benefit later, but they hope future patients will benefit. [12:21] That gives them a sense of control and hope that things will be better for the next generation. We all want that, especially in medicine, in something that we don't have a very deep understanding of. [12:58] Dr. Kuang received two HOPE Pilot Grants, one in 2018 and one in 2022. The first grant was awarded when she was a Fellow at the NIH. [13:05] That first grant explored some effects of eosinophilic depletion of pathogenic lymphocytes in hypereosinophilic syndrome and overlaps with EGIDs. Ryan asks for a broad overview of that research. [13:25] When Dr. Kuang was a Fellow at the NIH, they were doing a Phase 2 clinical trial, looking at "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients. [13:39] They included patients who had eosinophilic GI disease, often beyond the esophagus. They may have esophageal involvement, but sometimes their stomach is impacted, sometimes their large bowel is impacted, with related symptoms. [13:57] What Dr. Kuang and the team noticed in the trial was that just within that little group of patients, there were people who did well, and people who did much better than before, but would have recurrent symptoms, and with no eosinophils in their GI tissues. [14:16] The researchers wanted to know what was causing these problems for the patient. If you take eosinophils away, what other factors will impact the immune system of the patient, semi-long-term? [14:32] Their focus was on these groups of patients who had different responses. They looked at the white blood cells that had been previously described as being the responsible, "bad" T cells that lead to eosinophils in the gut. [14:49] They found that the patients who had recurrent flares of the disease had more of the bad T cells, and the patients who responded well and never complained again about symptoms did not. [15:03] That allowed researchers to identify that there were subsets of patients with the disease that they were calling the same thing. [15:18] Dr. Kuang says that work also led them to find that those cells were being reported in patients who had food allergies for which they needed an epinephrine auto-injector. [15:27] The researchers were curious whether that was just a food allergy issue, or only applied if you had food allergies and eosinophilic GI disease. That HOPE project allowed them to do a pilot study to look at food allergy patients, too. They did, and published it. [15:45] They published that in patients who have a food allergy and have these T cells, the insides of those cells make different messages for the immune system than the ones that the researchers had previously described. [16:01] In looking for why there were differences in those responses, they accidentally found that there were differences inside these cells in a completely different disease, which also had these T cells. [16:21] Dr. Kuang says that the finding was kind of a surprise. If they had found anything in the eosinophilic GI disease patients, that would have been good. They also looked at the epithelial cells and the structure of the GI lining. [16:42] Even though there were no eosinophils in the GI lining in the patients who had been treated with a biologic that depleted eosinophils, their GI lining still looked like the GI lining of patients who had eosinophilic GI disease. [16:55] Dr. Kuang asked what was creating those spots. Our gut lining sheds, so there should have been an opportunity for the GI lining to turn over and look new. Something was there, making signals to create these spots. They did a different publication on that. [17:21] The data from the HOPE Pilot study allowed Dr. Kuang to apply for larger grants. It allowed her to propose to the company that made this drug, when they did the Phase 3 trial, to insert into that special study the study on eosinophilic GI disease. [17:48] Do patients with eosinophilic GI disease do better or worse on this drug, and how do the T cells look in that trial? That HOPE Grant gave Dr. Kuang the data to ask the drug company to give her money to study it in an international cohort of patients. [18:17] There were only 20 patients in that first NIH trial, who gave a year of their life, coming to NIH all the time. They continued to be in the study until the drug was approved for asthma. [18:28] Dr. Kuang says the main reason the company did the Phase 3 trial, which is expensive, and the market share is not huge because it's a rare disease, is that two of the patients went to bat for this disease population. [18:47] The two patients went and showed the business people what they looked like before, what the drug had done for them, and how their lives had changed. It wasn't the doctors or the great paper from the trial, but the patients who convinced the company. [19:01] Dr. Kuang says she was so floored by that and moved by what they did for the community. She is grateful. [19:24] Since the Phase 3 trial, Dr. Kuang and the other researchers realized they had not fully studied the eosinophils. They had studied them in part. They found differences in response. This inspired the second APFED HOPE Pilot Grant. [21:19] In 2022, Dr. Kuang received a two-year APFED HOPE Pilot Grant to examine how blood eosinophils in Eosinophilic Gastrointestinal Diseases differ from those of other eosinophilic diseases and how T cells in EGIDs differ from those in food allergies. [21:49] Dr. Kuang says normally, the biggest place of residence for eosinophils is the GI tract. That's where they are normally seen in people who do not have eosinophilic disorders. [21:59] People who have eosinophilic disorders that attack other parts of the body, asthma, and rarely, the heart. Dr. Kuang was curious to know why one person and not the other? [22:15] Patients who have eosinophilic GI disease often ask, How do you know this high level in the blood is not going to attack my heart or my lungs in the future? Dr. Kuang does not know. [22:29] Dr. Kuang says, looking at the cohort at the NIH, that for many patients who have both GI organ involvement and some other space, when they first went to see a provider, their first complaint was a GI condition. [22:54] If the doctor had only diagnosed a GI condition, nothing else, that would have been wrong. Those patients may not have been monitored as well. A third of the patients originally presented like that. [23:11] What that meant was that we should be paying attention to patients who have GI disease who have lots of eosinophils in their blood. Moving forward, if there are new complaints, we need to investigate. We can't forget they have that. [23:27] Dr. Kuang asks, Wouldn't it be great if we had a better tool than needing to wait? Wouldn't it be great if we had a biomarker that said the eosinophils have switched their target location and are going somewhere else? [23:41] One way to do that is to take different groups of eosinophils and look for differences between those that never target the GI tract and those that do. In patients who have EoE, the eosinophils only target or cause problems in the esophagus. [23:58] Are their eosinophils any different than those of a healthy person, with none of these conditions? That was the goal of that study. [24:10] T cells are another type of white blood cell. They contain a memory of foreign things they have encountered, which allows them to glom onto flu, COVID, peanuts, pollen, that kind of thing. They remember. [24:32] Dr. Kuang says they learned that T cells, at least in the mouse model, are required in the development of eosinophilic esophagitis. The mice in the old study, where mice were forced to develop EoE, did not get EoE if you removed their T cells. [24:50] In the first APFED HOPE grant study, Dr. Kuang found T cells in the blood and tissue of both EGIDs and food allergy patients, but the insides of the T cells were different. The food allergy patients were children recruited by a pediatric allergist. [25:19] In the second APFED HOPE grant study, at Northwestern, Dr. Kuang recruited her adult food allergy patients. That was a way to validate what they found in the first study and move further to better characterize those T cells in the two different diseases. [25:47] Dr. Kuang says we're at a point where we've recruited a lot of people. She says it's amazing what people are willing to do. It's very humbling. [26:06] Dr. Kuang's team in the lab is really great, too. To accommodate patients, they would see them after work, if that's what they had to do to isolate eosinophils. So they did that, and now they are in the process of analyzing that data. It's really exciting. [26:28] What's exciting is that they are seeing results that show that eosinophilic GI disease patients have circulating eosinophils that are different from the eosinophils of people who don't have GI involvement, and from people who have EoE. [26:46] The EoE patients have eosinophils different from those of healthy donors. Dr. Kuang says there's a lot of promise for perhaps unique signatures that could help define these conditions; maybe someday without biopsying, but that's a long time away. [27:16] Dr. Kuang says they will focus on some candidate targets and try to recreate some of that in a dish with eosinophils from healthy people. [27:26] What are the signals that lead eosinophils to do this, and can we translate that back to available drugs that target certain cytokines or other pathways, and maybe give some insight to develop drugs that target other pathways for these diseases? [28:17] Ryan thinks it's exciting that this research is narrowing in on not only the different symptoms, but also how the eosinophils are acting differently in these populations. [28:44] Dr. Kuang is super excited about this research. You could imagine that all eosinophils are the same, but you don't know until you look. When they looked, using the newest technology, they found there were differences. [29:33] Dr. Kuang says it is thought that T cells respond to triggers. We don't think eosinophils have a memory for antigens. T cells do. That's one of their definitions. When T cells react to a trigger, they give out messages through cytokines or by delivery. [30:20] Those are the messages that recruit eosinophils and other cells to come and stir up some trouble. [30:28] In the mouse model, where you don't have the T cells, and you don't get eosinophilic esophagitis in the particular way they made it happen in a mouse, that middle messenger is gone, so the eosinophils don't know where to go. [30:44] With drugs that take out eosinophils, you think that you've gotten rid of the cell that creates all the problems. It shouldn't matter what the message says because there's no cell there to cause the damage. [30:58] What Dr. Kuang learned is that, at least in certain eosinophilic GI diseases, that's not true. You erase the eosinophils from the picture, but that message is still coming. [31:10] Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there? [31:24] It's important to study both, because one is the messenger and the other is one of the actors. Whether all of the actions taken by eosinophils are bad, or maybe some of them were meant to be good, we have yet to learn. [31:40] At the moment, we're using it as a marker for disease activity, and that may change in the future, as we learn more about the roles of these cells in the process. [31:50] We have drugs now that target eosinophils and drugs that target T cells. Dr. Kuang thinks it's important to study both and to study the impact of these drugs on these cells. [32:02] You could theoretically use these drugs to understand whether, if someone responds to it, what happens to these cells, and if someone doesn't respond to it, what happens to these cells, and how this disease manifests in this flavor of patients. [32:54] Dr. Kuang says, Often in science, we take a model. We think this works this way. Then, if this works this way, we expect that if we remove this, these things should happen. We did that with the first clinical trial, with NIH patients. [33:10] It didn't quite happen the way we thought, so we had to go looking for explanations. These were unusual setbacks. Sometimes you have unusual findings, like the food allergy part. [33:24] When Dr. Kuang went to Northwestern, she saw different cohorts of patients than she saw at NIH. She saw people who were seen every day, which is a different spectrum than those who are selected to be enrolled in a study protocol at the NIH. [33:42] That broadened her viewpoint. It's maybe not all food-triggered. They were seeing adults who'd never had food allergies or asthma their whole life, and they had eosinophilic esophagitis suddenly as a 50-year-old. There's a significant group of them. [34:10] What Dr. Kuang learned and tries to be open-minded about is that where you train, what sorts of patients you see, really shape your viewpoint and thinking about the disease process and the management process. [34:24] Dr. Kuang says she was so lucky to have experienced that at a quaternary care referral center like the NIH and at an academic center like Northwestern, where there are fantastic gastroenterologists who see so many of these patients. [34:56] Dr. Kuang and an Allergy Fellow knew they were going to get a wonderful data set from the NIH patients they had recruited, so they thought they had better look deeply at what had been learned before with older technology, with mice and people. [35:13] They decided to gather previous research, and that ultimately got published as an article. From that research, they learned that people did things in many different ways because there was no standard. They didn't know what the standard should be. [35:28] Different things you do to try to get eosinophils out of tissue impact how they look, in terms of transcript, gene expression, and what messages they make to define themselves as an eosinophil. [35:43] They also learned that because eosinophils are hard to work with, they die easily, and you can't freeze them and work on them the next day; you can introduce issues in there that have to be accounted for. [35:59] They learned that as an eosinophil research community, they ought to come up with some standards so that they can compare future studies with each other. Dr. Kuang says it was impossible to compare the old studies that used different premises. [36:50] Dr. Kuang says we need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data. It's hard to use the old data. [37:57] Dr. Kuang says they get fresh blood from patients, and because eosinophils are finicky, they need to be analyzed within four hours, or preserved in a way to save whatever fragile molecules are to be studied. [38:19] If you let it sit, it starts dying, so you won't have as many of them, and they start changing because they're not in the body. Dr. Kuang experimented with putting a tube of blood on the bench and checking it with the same test every two hours. It changes. [38:38] Four hours is a standard to prevent the eosinophils from dying. Patients need treatment. If a patient is hospitalized and needs treatment, Dr. Kuang's team needs to be there to get a sample before treatment is started. [39:03] The treatment impacts it, changing the situation. Much of the treatment, initially, is steroids. When you give lots of steroids, the eosinophils go away. It's no good to draw their blood then. [39:27] Dr. Kuang also gets a urine sample. The granules of the eosinophils can get into the urine. As they study people with active disease, they want to capture granule proteins in the urine as a less invasive way to monitor activity in different disease states. [40:04] The patient just needs to give Dr. Kuang either arm and a urine sample. [41:04] Dr. Kuang explains, you can count your eosinophils after four hours, but to study them, they have different flags of different colors and shapes. Those colors and shapes may mean that it's an activated eosinophil, or they may have other meanings. [41:41] Dr. Kuang focused on markers that look at whether it's going to spill its granules and some traditional markers of activation. [41:50] Everyone chooses a different marker of activation. So they decided to look at as many as they could. One marker is not sufficient. They seem to be different in different conditions. The markers are on the surface; you need to analyze them right away. [42:20] Then, Dr. Kuang breaks open the eosinophils and grabs the messenger RNA. They preserve it to do sequencing to read out the orders to see what this eosinophil is telling itself to make. RNA chops up messages. [43:00] When you open an eosinophil, a protein you find is RNA, which chops up messages, destroying parts of the cell. You want to save the message. There's a brief time to analyze the eosinophil. Dr. Kuang works to preserve and read the message. [44:04] Dr. Kuang hopes someday to run a tube of blood, look at the flags on the eosinophils, and say, "I think your eosinophilic GI disease is active," or "You have a kind of eosinophilic GI disease we need to monitor more frequently for organ damage." [44:38] If another patient doesn't have those flags, Dr. Kuang could say, "I think the chances that you're going to have involvement elsewhere are low." That can give reassurance to folks who are worried. [45:15] Dr. Kuang hopes that someday we can understand better why some people have food allergies vs. eosinophilic GI disease. They both have T cells, but the T cells have different packages inside with messages to deliver. [45:34] Every day, Dr. Kuang has to tell patients she doesn't have that answer. Someday, she hopes she can tell a patient she does have that answer. [46:35] Dr. Kuang tells about an NIH grant she's excited about and the patients she recruits after therapy, or elimination diets, to examine eosinophils and T cells, to see the impacts their treatments or diets have had on eosinophilic GI disease. [47:18] Dr. Kuang believes there will be predictors of who will respond to an elimination diet and who will respond to steroid therapy. She hopes one day to have that, rather than going through rounds of six to eight weeks followed by a scope. [47:34] If you have an elimination diet for six to eight weeks, every time you add back a food, you have to do a scope. Dr. Kuang says it would be great if you could be more precise ahead of time for therapy. [47:48] Dr. Kuang says these wonderful drugs selectively take out parts of the pathway in the immune system. They provide real-life opportunities to ask, why is this important in human biology and the human immune system? [48:15] Dr. Kuang finds the knowledge itself fascinating and useful. She hopes it informs how we choose future drugs or therapeutic avenues to get the best we can out of what we've learned, so we have more targeted ways of treating specific diseases. [48:48] Ryan is grateful for all the research happening for the eosinophilic disease community and all the patients participating in the research. He asks Dr. Kuang how a patient can participate in research. [49:12] There are lots of ways to be involved in research. Dr. Kuang says her patients come away from participating in research feeling good about having done it. [49:22] Answer a survey, if that's what you have bandwidth for. Where therapies are changing, being a part of a community is good for the community, for the future, but it's good for you, too. It's healing in ways that are not steroids or biologics. [49:58] Being part of a community is healing in ways we all need when we feel alone and bewildered. You're not alone. [50:12] There are many ways to participate: APFED, CEGIR, individual institutions, and clinical trials. They all have different amounts of involvement. It's worthwhile to participate, not only for future patients but for yourself. They're fantastic! [50:56] Dr. Kuang talks about the privilege as a physician of working with APFED and other organizations to do this work. [51:09] Holly thanks Dr. Kuang for sharing all of this research and exciting information. [51:25] Dr. Kuang is excited about what her group is doing and is hopeful. Besides showing up for this disease, we have to show up for research, in general, in this country. It's a dark time for NIH research funding. [51:55] Dr. Kuang asks the young listeners who are thinking of choosing a field to see the potential and get into it, study this, and believe that there's going to be a future with a more nurturing research environment. [52:36] Dr. Kuang would hate to lose generations of scientists. She says that once she was a little girl who was trying to be a scientist. Her parents had no connections with scientists or doctors, but she was able to get into research, and she thinks you can, too. [53:48] As a graduate student, Ryan has always been interested in trying to improve things, and he sees hope on the horizon. He's very grateful to the APFED community for supporting these research HOPE Pilot Grants. [54:17] Ryan is very grateful to Dr. Kuang for joining us today. [54:22] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes. [54:28] If you're looking to find a specialist who treats eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist. [54:37] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections. [54:57] Dr. Kuang thanks Ryan and Holly and says she enjoyed the conversation. Holly also thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode. Mentioned in This Episode: Fei Li Kuang, MD, PhD, Allergist and Immunologist, Northwestern Medicine Grants and publications discussed: Apfed.org/blog/apfed-announces-2018-hope-apfed-hope-pilot-grant-recipient/ Apfed.org/blog/fei-li-kuang-hope-pilot-grant-award/ Pubmed.ncbi.nlm.nih.gov/39213186/ Pubmed.ncbi.nlm.nih.gov/37487654/ APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda. Tweetables: "I think the patients that you meet in a clinical trial, especially in a special place like NIH, occupy a space in your heart — I don't mean to be all too emotional about this — that makes you want to keep working on the subject area." — Fei Li Kuang, MD, PhD "When I was a Fellow at the NIH, we were doing a Phase 2 clinical trial, looking at, for want of a better word, "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients." — Fei Li Kuang, MD, PhD "We're at a point where we've recruited a lot of people. I've had patients drive from the northern part of Illinois … come down and give me blood. It's amazing what people want to do and are willing to do. It's very humbling, actually." — Fei Li Kuang, MD, PhD "You erase the eosinophils from the picture, but that message is still coming. Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there?" — Fei Li Kuang, MD, PhD "We need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data." — Fei Li Kuang, MD, PhD "I think it's worthwhile to participate [in a clinical trial], not only for the future people but for yourself." — Fei Li Kuang, MD, PhD Guest Bio: Fei Li Kuang, MD, PhD, is currently an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She is a graduate of the Albert Einstein College of Medicine Medical Scientist Training Program with both a PhD in Cell Biology/Immunology and an MD. She completed her Internal Medicine Residency at Columbia University, New York Presbyterian Hospital in New York City, she did her Fellowship in Allergy and Immunology at the National Institute of Allergy and Infectious Disease (NIAID) in Bethesda, Maryland. She is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples.
The origin of life is one of the biggest challenges to secular scientists. Hear a leading expert expound upon a myriad of reasons why! There will be some work for these two. He shared his screen and showed some videos, but he sent me links to use that should be better (i.e., cut-out the live version and insert the video taken from the links he's giving us. See below my signature for those links).Also, his mic went out a number of times and he had to fix it quickly. That should all be edited out. Let me know if you have any questions.1) from Verisasium YouTube Channel, "The most controversial idea in biology":https://youtube.com/clip/UgkxDPCtBoV57kP7N3sy9BoBwKzaWOpKqk_c?si=iXXH4u0s19BVFOWo2) From Long Story Short, "Debunking popular science videos on the origin of life and RNA world"https://youtu.be/dKoWpWGS-zY?si=Ls8R0L6auKsASnFF from 4:28.6 to 4:50.93) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxmsQ_bxpMaYtHqtjeDsrkkqEONYRNG5Yo?si=wg3LPhwxdR8qUPGz4) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxrdEiIUifweDIR99ro_Z0Oe_P7D5N-UqE?si=io7tIULpVwLXQVC25) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxDfnmez63NDacsa2jp0S4o_QDdobuo8t1?si=y5R36fqCcVuLH8qU6) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxhE4pJPHFRDfkkGSlG_qTuYKulzGRxr59?si=9z5X5r9wDMWazKwM
We're pleased to feature Steve Brown in this episode of Wolf Greenfield's Alumni Spotlight series. He was previously a technology specialist in Wolf Greenfield's Biotechnology Practice. Today, Steve serves as Associate General Counsel at Orna Therapeutics. Orna is reshaping RNA therapeutics to open an entirely new world of possibilities in the treatment of disease.Here are some highlights from Steve's turn in the Alumni Spotlight on IP Talk with Wolf Greenfield.00:47 - Steve's current responsibilities at Orna02:19 - Making the transition from a law firm into corporate roles03:26 - An overview of Orna Therapeutics05:18 - Steve's favorite memory of Wolf Greenfield07:25 - When Steve thinks of his time at Wolf Greenfield, what comes to mind?09:10 - Steve's dream travel destination10:09 - His favorite movie###
SpaceTime with Stuart Gary | Astronomy, Space & Science News
SpaceTime with Stuart Gary - Series 28 Episode 145In this episode of SpaceTime, we explore groundbreaking discoveries that deepen our understanding of the origins of life and the dynamics of our galaxy.Sugars and Stardust: Insights from Asteroid BennuNASA's Osiris Rex mission has returned samples from the asteroid Bennu, revealing the presence of biologically essential sugars, including ribose and glucose, along with a unique gum-like substance never before seen in astromaterials. These findings, published in Nature Geoscience and Nature Astronomy, suggest that the building blocks for life were widespread throughout the early solar system. The discovery of ribose supports the RNA world hypothesis, indicating that RNA might have been the first genetic material. Additionally, the presence of glucose hints at the early energy sources available for life on Earth.Stars Defying the Black HoleAstronomers have observed numerous stars in stable orbits around Sagittarius A, the supermassive black hole at the center of our galaxy. This discovery, reported in Astronomy and Astrophysics, challenges previous assumptions that these objects were merely clouds of dust on a collision course with destruction. Instead, the new data from the ERIS Enhanced Resolution Imager and Spectrograph reveals a dynamic and stable environment around the black hole, providing a unique laboratory for studying interactions between black holes and stars.Martian Mystery Solved?A new radar technique employed by NASA's Mars Reconnaissance Orbiter has cast doubt on the existence of a suspected underground lake beneath the Martian South Pole ice cap. Initial signals that suggested the presence of liquid water have been reinterpreted as possibly being layers of rock and dust. This innovative approach opens new avenues for investigating subsurface resources on Mars, which could have significant implications for future exploration.www.spacetimewithstuartgary.com✍️ Episode ReferencesNature GeoscienceNature AstronomyAstronomy and AstrophysicsGeophysical Research LettersBecome a supporter of this podcast: https://www.spreaker.com/podcast/spacetime-your-guide-to-space-astronomy--2458531/support.
As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we're showcasing the innovative companies presenting at the DealFlow Discovery Conference and the executives behind them. Today's spotlight features Robert Bitterman, CEO & President of Phio Pharmaceuticals, who discusses how the company's INTASYL™ RNA platform is engineered to reactivate immune cells directly within the tumor microenvironment — opening the door to safer, more targeted cancer therapies. In this episode, Adam Torres interviews Robert Bitterman, CEO and President of Phio Pharmaceuticals, about the company's mission to create new pathways toward a cancer-free future. Robert explains how Phio's INTASYL™ platform uses targeted RNA technology to reactivate immune cells inside the tumor microenvironment, potentially offering a safer and more effective approach to treating cutaneous squamous cell carcinoma. He also shares early clinical data, the next steps toward pivotal trials, and why education and innovation remain at the heart of Phio's work. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices
Janelle Connell is a registered dietician and personalized nutrition expert working with Viome to help people discover how to properly eat based on their individual microbiome and gene expression.Grant Antoine, ND brings his expertise in medicine and nutrition to unlock the connections between what is happening in the microbiome and the effects we see play out in our body over time.Key takeaways from this discussion:Understanding microbiome activity rather than just composition is crucial for personalized health approachesRNA analysis reveals microbe activity rather than just presence, providing more actionable health insightsThis technology allows for personalized food and supplement recommendations based on individual microbiome activityEarly detection and prevention through microbiome testing can help delay or prevent chronic diseaseFiber is essential for feeding beneficial gut microbesPersonalized nutrition should consider individual glycemic responses to foodsSupporting the microbiome during and after antibiotic use is important for healthPersonalized supplement formulations are created based on individual test resultsViome uses RNA sequencing technology to analyze microbiome activity rather than just composition, providing personalized nutrition recommendations. Click this link viome.com to receive a $50 discount on your first test kit. Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys
Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Dr. Dale: When I run into a problem, the first thing I have to do is tell myself, don't be afraid. You've solved other problems in the past. You can solve this one.Millions of people worldwide face the devastating impact of cancer, with countless lives lost each year to tumors that no longer respond to existing treatments. Dr. Dale Walker, Co-founder and CEO of The Burlington HC Research Group (BHCRG), is working to change that narrative with her groundbreaking development of a new family of anti-cancer drugs. These drugs have the potential to revolutionize treatment for cancers that have become resistant to current therapies.“We tested our drugs against 15 human cancer cell lines, representative of seven different tissues, and the drug works against all of them,” Dale explained. In the U.S. alone, over 600,000 people die annually from cancer, often because their tumors no longer respond to treatment. Dale's research offers a glimmer of hope for patients and their families.Unlike traditional drug development that focuses on a single compound, Dale and her team have created a family of drugs—called BRG drugs—by combining two FDA-approved ingredients in a novel way. These drugs not only enhance the effectiveness of existing cancer treatments but also demonstrate the ability to kill nearly all cancer cells after a single dose in preclinical studies. “Most anti-cancer agents just slow tumor growth. Ours hit both marks—killing tumor cells at a safe dose level,” she said.With such promising results, Dale and her husband Vernon, who co-leads the research, are pushing forward. However, taking these drugs through the necessary safety and efficacy tests requires significant funding. To accelerate progress, BHCRG is raising capital through a regulated crowdfunding campaign on the FundingHope platform. Crowdfunding offers a faster alternative to traditional funding sources, enabling the Walkers to bypass lengthy government grant timelines.“Crowdfunding is a lifeline. We have family members and friends with cancer. We can't wait years,” Dale shared. For investors, the opportunity to back a potential game-changing cancer therapy is compelling, both for its societal impact and long-term financial potential.Dale's passion and perseverance shine through in her work. Her innovative approach to drug development could save countless lives. Supporting her mission on Funding Hope isn't just an investment in a company—it's an investment in hope.tl;dr:Dale Walker shares her innovative work on new anti-cancer drugs targeting resistant tumors.BHCRG's BRG drugs show promising preclinical results, killing almost all tumor cells with one dose.Dale explains crowdfunding's role in accelerating drug development for life-saving cancer treatments.She discusses perseverance as her superpower, solving challenges by embracing and examining problems.Today's episode highlights how crowdfunding enables investors to support impactful innovations in healthcare.How to Develop Perseverance in Problem-Solving As a SuperpowerDale's superpower is her extraordinary ability to solve complex problems and persevere through challenges. In today's episode, she explained, “When I run into a problem, the first thing I have to do is tell myself, don't be afraid. You've solved other problems in the past. You can solve this one.” Dale emphasized that problems often contain valuable information that leads to solutions, encouraging others to examine challenges closely rather than avoiding them.After discovering that an FDA-approved drug had antiviral activity, Dale faced a seemingly insurmountable challenge: making the drug work effectively in people. “I thought, I will not be able to solve this problem. It's too hard,” she admitted. Yet, she persevered, combining the drug with another FDA-approved ingredient. This breakthrough created the BRG family of cancer drugs, which kill nearly all cancer cells in preclinical studies after a single dose. Her ability to persist through doubt and difficulty exemplifies her superpower.Tips for Developing Perseverance in Problem-Solving:Acknowledge Your Strengths: Remind yourself that you've solved tough problems before and can do it again.Examine Problems Closely: Instead of avoiding challenges, look for clues within the problem itself to guide solutions.Break Down the Problem: Address each component of the challenge one step at a time.Stay Focused: Resist the urge to pivot too quickly; often, solutions lie in persistence.Find Inspiration: Remember the impact your work can have on others to stay motivated.By following Dale's example and advice, you can make perseverance in problem-solving a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDale M. Walker (she/her):Co-founder, owner, and Chief Executive Officer, The Burlington HC Research Group, Inc. (BHCRG)About The Burlington HC Research Group, Inc. (BHCRG): BHCRG is working to advance a new family of investigational drugs called BRG Therapeutics. Based on pre-clinical studies, two members of this family show potent anticancer activity across human cancer cell lines representing seven different tissues of origin, including lung cancer (four subtypes), prostate cancer (three types), triple-negative breast cancer (two types), ovarian cancer (two types), pancreatic cancer (one type), pleural mesothelioma (two types), and pre-myeloblastic leukemia (one type, tested with a single BRG drug). In tissue-culture models, BRG drugs demonstrate an unusually strong ability to eliminate nearly all cancer cells after a single dose while achieving this result at doses that are non-toxic to normal human cells. Each BRG drug delivers two active ingredients, and the primary component (ingredient #1) also inhibits the replication of viruses spanning all three major viral genome classes—DNA viruses, RNA viruses, and reverse-transcribing/retroviruses—with activity shown in vitro against influenza, COVID-19, HIV, and Ebola and other viruses. Although such breadth is uncommon and has led some observers to believe no drug could achieve these effects, the evidence shows that the human body naturally produces several essential compounds with similarly broad anticancer and antiviral functions; BRG drugs work through analogous biochemical mechanisms but produce stronger effects in controlled laboratory studies. These naturally occurring comparators include N-acetylcysteine, glutathione, and vitamin C (only at pharmacologic doses). Taken together, BRG Therapeutics represents a next-generation, multi-targeted approach designed to overcome one of the central limitations of modern oncology—drug resistance—by restoring normal cellular regulation, reactivating p53, correcting redox imbalance, and neutralizing reactive species to selectively eliminate cancer cells while preserving healthy tissue.Website: bhcrg.comCompany Facebook Page: facebook.com/profile.php?id=61584197824692Other URL: invest.fundinghope.com/offering/brg/detailsBiographical Information: My husband Vernon and I work together as a team, and we have advanced BRG therapeutics to their present state of development by collaboration. We both are veterinarians with advanced training in pathology, so that make us ‘veterinary pathologists'. Vernon also has a PhD in experimental and molecular pathology. What many people do not know is that veterinary pathologists have key roles in drug development and safety testing. Before the discovery of the BRG drugs, most of our work focused on health risks from human exposures to environmental, workplace, or medicinal agents/compounds. We were working with BRG active ingredient #1, which is FDA-approved as the active form of a cell protective drug – that means that it protects normal cells from the damaging effects of radiation and some chemicals. We were testing the ability of this agent to protect normal cells from the deleterious effects of some of the first drugs like AZT developed to treat HIV. We were surprised to learn that this cell protective drug had antiviral activity all on its own. Even though this active ingredient had been around for several decades, no one had ever reported these results before we did. We soon learned why we were the first to make this discovery - the active ingredient of this cell protective drug worked well in tissue culture as an antiviral agent, but antiviral effects were not achieved in living animals. This sent us on a long road figuring out why this was – after all, this agent worked to protect normal cells in living animals and people, so why would it not work as an antiviral agent in the same animals and people? It actually took several years to understand the nature of the problems, and even more time to figure out a solution. That solution was the BRG therapeutics.Vernon and I had little experience studying viruses, and much more experience studying cancer and anticancer drugs, and we knew that this active ingredient had anticancer activity, so we decided to start with testing a BRG drug as an anticancer agent. Our first experiment in a human, pre-myeloblastic leukemia cell line showed us anticancer effects beyond anything that we could have imagined. We were so excited, but we still had a long journey of work and discovery ahead of us. To date we have tested two BRG drugs and they kill cancer cells in all human cancer cell lines tested to date (one drug tested in 15 human cancers, the other tested in 14). A paper summarizing these results was published in 2023.LinkedIn Profile: linkedin.com/in/dale-m-walker-bhcrgPersonal Facebook Profile: facebook.com/profile.php?id=61556212335476Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and SuperGreen Live. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Superpowers for Good Live Pitch, December 11, 2025, at 8:00 PM Eastern / 5:00 PM Pacific, will bring together four mission-driven founders—Fran Maier (BabyQuip), Farooq Zama (CureValue), Andrei Evulet (Jetoptera), and Erin Martin (Pump For Joy)—as they present their companies live to a national audience on e360tv, YouTube, and LinkedIn. Hosted by Devin Thorpe, CEO and Founder of The Super Crowd, Inc., this special broadcast showcases entrepreneurs raising capital to solve real-world problems across family travel, healthcare access, disaster response aviation, and maternal health. Viewers are encouraged to watch the live pitches and then continue the experience by joining the Private Investor Session immediately following the broadcast, where attendees can engage directly with founders, ask deeper questions, and explore their active investment offerings in a focused, off-air environment. Whether you are an active investor or simply interested in the future of mission-driven innovation, this event offers a rare opportunity to witness purpose-driven companies in action and connect with them directly after the show.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on December 16, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, December 17, 2025, at 12:00 PM Eastern, will feature Devin Thorpe, CEO and Founder of The Super Crowd, Inc., leading a session on “Designing a Winning Marketing Strategy for Your Investment Offering.” Drawing on his deep experience in impact crowdfunding and investment storytelling, Devin will break down the essential elements of building a marketing strategy that attracts, engages, and converts potential investors. Participants will learn how to identify and reach the right audience, craft messages that build trust, and develop a promotional plan that supports sustained momentum throughout a raise. Whether you're preparing for your first regulated investment crowdfunding campaign or looking to strengthen an ongoing one, this SuperCrowdHour will provide the insights and practical frameworks you need to elevate your offering and boost investor participation.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.CfPA President-elect's Vision for 2026 with Brian Belley, December 17 at 2:00 PM ET – reserve your spot now!If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe
Yogev Debbi and Prof Avi Schroeder (Technion Israel Institute of Technology), co-founded Mana bio along with Dr. Kira Radinsky and Roy Nevo. They are leveraging data, machine learning and high throughput screening to design novel Lipid NanoParticles for targeted extrahepatic delivery of nucleic acid therapeutics and vaccines. Lipid nanoparticles are microscopic fatty bubbles that deliver genetic medicines into your cells—think of them as the FedEx trucks of molecular biology. Remember the mRNA vaccines that saved millions during COVID? They used lipid nano particles as the delivery vehicle.. The little secret behind those vaccines is that we got lucky. Those lipid nanoparticles worked beautifully for the liver and immune system. But if you try to deliver RNA to your brain, your lungs, or a tumor, those would be a massive failure! Scientists are still running thousands of experiments hoping to stumble onto the right formulation. This actually was my postdoc work as well, which makes this episode very special. I always wished there was a better way to design these delivery vehicles—and that's exactly what today's guests have built with AI." We talk about how they founded and currently building Mana Bio- a big part around how biologists and chemists can interact with technologists, especially data and AI geeks to build something important. Their story provides a great framework for scientists and tech folks to work together. Shownotes: https://www.mana.bio/ How Avi got started using data/AI to design LNPs Optimizing LNP formulations targeting different organs Working with Bob Langer and Dan Anderson @MIT Yogev transitioning to gene editing Defining the problem & cross disciplinary conversations and projects Language that helps interactions between scientists and software/AI folks Deepdive into the platform- building data sets Data scraping, validation, improvisation, new data generation (both positive and negative data) Cleaning data and normalization Work in the wet lab: 'I trust my colleagues and believe data can be replicated" Data moats: Proprietary data vs public data Daily routine in the lab and interactions with the data/AI team Cross Functional dynamics Scientists trying to save money vs optimizing for more valuable time Lab hypothesis predictions vs AI predictions: competitive spirit Factoring in errors by the machines and humans Business model: Building customized solutions for drug delivery Potentially becoming a pharma company Regulatory affairs Fears that keep them up Dynamics of a diverse founding team: Roy Nevo and Dr. Kira Radinsky (the other two co founders) Message to academia: "Publish more data- including failures. This will accelerate science" Omri Drory, Kira Radinsky https://www.youtube.com/watch?v=y5hX3vq3iNk
Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008
It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as they hear how feeding Farmatan to bred cows now can help prevent scours this upcoming calving season. Plus news, markets, updates, bred cow prices and lots more on this all-new episode of The Ranch It Up Radio Show. Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. How To Prevent Calf Scours: Feed Farmatan Feed Farmatan To Prevent Scours This Upcoming Calving Season Calving season is getting ready to start for many producers and for some others it is still a ways away yet. Regardless, we need to get a jump on scours and make sure each and every calf that hits the ground has the best chance of survival. A simple solution… FARMATAN from Imogene Ingredients. WHAT CAUSES SCOURS IN BEEF CATTLE/CALVES Clostridia-Enterotoxemia The most common form of Clostridium in cattle is caused by Clostridia perfringens. The gram-positive bacteria are a challenge due to its ability to form spores and lay dormant for long-periods of time. The bacteria reproduce by releasing spores into its environment (soil, feed, manure). The spores can even lay dormant in the animal's intestine until opportunity presents itself. Infection takes place either through ingestion of spores or through an open wound. The most severe cases happen within the first month of a calf's life, and can result in sudden death. Clinical Signs Diarrhea - Bloody, Mucus Present, Bubbly Dehydrated Bloat Blindness Prevention/Treatment: Prevention can be difficult due to the Clostridia spores being extremely durable and present almost everywhere. Complete cleanout and disinfection between calves is helpful, but not always effective. A good vaccination program will reduce clinical disease. The best method is to develop good gut health and the immune system of the calf. Farmatan has been shown to strengthen the intestinal wall, helping to prevent infection from taking hold. Coccidiosis Cattle are host to numerous species of Coccidia, a single-celled protozoal parasite. Infection and clinical symptoms can happen any time during a calf's life, with the most severe reaction usually occurring between 3-6 weeks of age. The life-cycle of coccidia requires time to infect the intestine causing destruction of the mucosal and epithelial lining. The oocytes mature outside the host in warm, moist environments before being consumed, causing infection of a new host. Clinical Signs Diarrhea - Watery, Bloody Depression Weight Loss Prevention/Treatment: Prevention of Coccidiosis is possible by keeping young calves separate from older animals, providing clean water and feed, and dry conditions. Isolation of infected animals is key to preventing transmission. Keeping the pen dry is the most important step a farmer/rancher can take in preventing Coccidiosis. Treatment can have a good impact on reducing secondary disease, and speeding up recovery time. Farmatan has been shown to disrupt the reproductive cycle of Coccidia; and may help strengthen the intestinal wall to prevent infection, in both the cow and calf. Coronavirus Bovine Coronavirus is a ubiquitous, envelope-viral disease, causing respiratory and enteric infection. There are many serotypes for this virus, making it difficult to test for, and create a vaccine. Coronavirus can present as either diarrhea and/or respiratory illness; transmitted through nasal discharge and/or feces. Animal reservoirs continue to spread the disease, and make eradication almost impossible. Clinical disease will likely occur between days 10-14, and present for up to 4 days. Clinical Signs Diarrhea - Watery Nasal Discharge Coughing Prevention/Treatment: Prevention is difficult due to wild animals transmitting the disease. Keeping wild animals out of animal enclosures is essential. Isolation of infected animals is critical to preventing the spread of Coronavirus. Adequate colostrum intake, along with a good vaccination program will help prevent clinical disease. Learn more about the positive effects of Farmtan's active ingredient on Coronavirus HERE. Cryptosporidium Cryptosporidium Parvum is a single-celled parasite responsible for causing infection in young calves. The infection takes place within the first four weeks of a calves' life, afterwards immunity has developed within the calf. The parasite is either passed from the cow or spread through infected water sources. Clinical Signs Diarrhea - Watery, Bloody, Mucus present Colic Depression Prevention/Treatment: Good sanitary conditions, especially clean water is essential in preventing transmission of cryptosporidium. Isolation of sick calves will help reduce the effect on the overall herd. There is some good effect of calves given adequate colostrum, however this is likely helping by reducing other pathogenic loads rather than a direct effect on Cryptosporidium, itself. Farmatan fed prior to calving has been shown to disrupt the life-cycle and reduce transmission from the cow. The direct action of Farmatan on the parasite makes it an excellent choice for treating calves. Learn more about the positive effect of Farmatan's active ingredient HERE. E-Coli Escherichia Coli is a bacterial infection that affects calves within the first week of their life. The bacteria colonize in the lower intestine and produce a toxin. The toxin causes excessive secretion of fluids. The zoonotic disease has special importance in food safety and human health. Colostrum and natural immunity are often not sufficient in preventing infection in cases of high bacterial concentrations. Clinical Signs Diarrhea - Creamy, Yellow Abdominal Pains Fever Vomiting Prevention/Treatment: The best prevention methods for E. Coli include: clean water, dry bedding/environment, isolation of infected animals, and vaccination. Treatment with antibiotics and oral fluids have great benefits in reducing clinical symptoms of the disease. Farmatan has been shown to reduce bacterial load and help prevent infection. Learn more about the positive effects of Farmatan's active ingredient HERE. Rotavirus Rotavirus in calves is caused by a virus belonging to the Reoviridae family, as a non-envelope RNA virus. Rotavirus is thought to be the most common cause of neonatal diarrhea in calves. The virus tends to affect calves between the age of 1-day-old up to a month, with most cases presenting within the first week of life. Shedding and reinfection can happen in older calves and cows. Clinical symptoms are rarely present after the first month of life; older animals tend to either be carriers or asymptomatic. The majority of herds have some level present, with transmission likely happening during or shortly after birth. Clinical Signs Diarrhea - Pale Yellow, Bloody Dehydrated Dull calves Reluctant to drink Prevention/Treatment: The ideal scenario is to prevent infection through, sanitary facilities (calving barn), outdoor calf housing, and a good vaccination program. Colostrum will provide much needed antibodies, protecting the calf before their immune system is fully developed to combat the disease. Farmatan fed prior to calving can help reduce the pathogen load of the cow, reducing the likelihood of transmission. Farmatan supplemented in the milk has been shown to decrease the virus' ability to cause infection and clinical disease. The best treatment for calves already presenting clinical disease is to administer oral fluids/electrolytes to rehydrate the calf. Learn more about the positive effect of Farmatan's active ingredient HERE. Salmonella Salmonella infection of cattle is caused by a variety of species within the family. While the disease is uncommon in cattle with little effect on calf health, it has massive implications for human health and food safety. The bacteria spreads through direct contact or contaminated feed & water. This disease is highly regulated by the USDA. The most severe cases of salmonella affect calves between the ages of 7-10 days old. Clinical Signs Diarrhea - Bloody (flakes of slough tissue), Watery, Mucus present Lethargic Fever Prevention/Treatment: Prevention is always the best option: provide clean water, feed, and bedding. Isolate infected animals, ensure adequate colostrum intake, and develop a vaccination program with your veterinarian. Treatment with antibiotics and fluids (oral or intravenous) greatly increases the survival rate of calves infected with Salmonella. Farmatan has been shown to help reduce the likelihood of infection by protecting the gut, and reduce recovery time of infected animals. LEARN MORE ABOUT IMOGENE INGREDIENTS PRODUCTS Paul Mitchell & Paul Martin on RFD TV Rural America Live! WATCH: https://vimeo.com/759549430/bd063fcc1f Beef Industry News Possible Slow Beef Trend in 2026 According To Rabobank Beef production by major global producers is expected to remain sluggish next year, according to analysts at the Dutch financial services cooperative Rabobank. The recent contraction in beef production is expected to affect major producers in Brazil, Canada and the United States, with New Zealand being likely to see the sharpest percentage drop in beef production, the Rabobank report predicted. Several issues are contributing to the 2025 decline and the expected drop next year, especially in light of limited cattle herds ready for slaughter in both the United States and Brazil, the report added. The long-term contraction of available cattle is being blamed for significant price hikes for retail beef in the last few years, Rabobank noted. Canada is experiencing a tighter pattern that has resulted in a decline of 41,000 metric tons of beef available for export in 2025 versus levels in 2024, according to the report. Canadian beef output in 2026 is expected to be “more limited” compared with this year for reasons also being experienced south of the Canadian border in terms of the available cattle herd. References: https://meatingplace.com/slower-beef-production-trend-to-continue-in-2026-rabobank/?utm_source=omeda&utm_medium=email&utm_cid=1103020073&utm_campaign=MTGMCD251201004&utm_date=20251201-1300 New World Screwworm Website Tracks Parasite There's a new way for producers and other stakeholders to track the fight against the New World Screwworm — a parasite that threatens live cattle herds. The USDA has launched a dedicated website with up-to-date information on the spread of the screwworm, which so far has been confined to cattle in several Mexican states near the U.S. border. The site includes resources for livestock producers, veterinarians, animal-health officials, wildlife experts, healthcare providers, pet owners, researchers, drug manufacturers, and the general public. Reports of the pest in Mexican cattle prompted the U.S. to halt cattle imports from Mexico back in May. USDA also committed $21 million to boost sterile fly production in Mexico as part of its response. The new website pulls together information from multiple federal partners, including the FDA, the Department of Energy, Homeland Security, the EPA, and the State Department. Reference: https://www.aphis.usda.gov/livestock-poultry-disease/stop-screwworm Nightshade In Corn Residue Could Be Toxic Have you noticed any black nightshade in your corn stalks that you are grazing or plan to graze? If these fields have too much black nightshade, be careful — it might be toxic. Black nightshade is common in many corn fields in the fall, especially those that had hail damage in the summer or any situation where the corn canopy became thin or open. It usually isn't a problem, but if the density of nightshade is very high, there is the potential that it could poison livestock. Almost all livestock, including cattle, sheep, swine, horses and poultry are susceptible. Black nightshade plants average about two feet in height and have simple alternating leaves. In the fall, berries are green and become black as the plant matures. All plant parts contain some of the toxin and the concentration increases as plants mature, except in the berries. Freezing temperatures will not reduce the toxicity. It is very difficult to determine exactly how much black nightshade is risky. Guidelines say that a cow would need to consume three to four pounds of fresh black nightshade to be at risk of being poisoned. These guidelines, though, are considered conservative since there is little data on the actual toxicity of nightshade plants. Fortunately, even though nightshade plants remain green fairly late into the fall, cattle usually don't appear to seek out nightshade plants to graze. However, green plants of nightshade might become tempting toward the end of a field's grazing period when there is less grain, husks or leaves to consume. References: https://www.nationalbeefwire.com/nightshade-in-corn-residue-grazing-could-be-toxic Featured Experts in the Cattle Industry Paul Mitchell – Imogene Ingredients https://www.imogeneingredients.com/ Follow on Facebook: @FarmatanUSA Kirk Donsbach – Financial Analyst at StoneX https://www.stonex.com/ Follow on Facebook: @StoneXGroupInc Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: Allied Genetic Resources: https://alliedgeneticresources.com/ American Gelbvieh Association: https://gelbvieh.org/ Axiota Animal Health: https://axiota.com/multimin-campaign-landing-page/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view Medora Boot: https://medoraboot.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Superior Livestock Auctions: https://superiorlivestock.com/ Transova Genetics: https://transova.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/ Wulf Cattle: https://www.wulfcattle.com/
The origin of life is one of the biggest challenges to secular scientists. Hear a leading expert expound upon a myriad of reasons why! There will be some work for these two. He shared his screen and showed some videos, but he sent me links to use that should be better (i.e., cut-out the live version and insert the video taken from the links he's giving us. See below my signature for those links).Also, his mic went out a number of times and he had to fix it quickly. That should all be edited out. Let me know if you have any questions.1) from Verisasium YouTube Channel, "The most controversial idea in biology":https://youtube.com/clip/UgkxDPCtBoV57kP7N3sy9BoBwKzaWOpKqk_c?si=iXXH4u0s19BVFOWo2) From Long Story Short, "Debunking popular science videos on the origin of life and RNA world"https://youtu.be/dKoWpWGS-zY?si=Ls8R0L6auKsASnFF from 4:28.6 to 4:50.93) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxmsQ_bxpMaYtHqtjeDsrkkqEONYRNG5Yo?si=wg3LPhwxdR8qUPGz4) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxrdEiIUifweDIR99ro_Z0Oe_P7D5N-UqE?si=io7tIULpVwLXQVC25) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxDfnmez63NDacsa2jp0S4o_QDdobuo8t1?si=y5R36fqCcVuLH8qU6) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxhE4pJPHFRDfkkGSlG_qTuYKulzGRxr59?si=9z5X5r9wDMWazKwM
Maria Barna is an authority on ribosomes – “life's most ancient and spectacular molecular machines.” Ribosomes make proteins in the body. There can be a thousand different types of ribosomes in a single cell, she says, each with a specific job to do. But sometimes things go awry and ribosomes get “hijacked,” leading to disease. Barna studies these “diabolical” variations to find new therapies to treat diseases ranging from cancer and COVID to Parkinson's. When diseases hit, it's all about the ribosomes, Barna tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Maria BarnaConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Maria Barna, a professor of genetics at Stanford University.(00:04:21) Origins of Ribosome ResearchMaria explains why ribosomes became the focus of her work.(00:06:14) Ribosome Function and ScaleRibosomes' functions and the energy required for their production.(00:08:28) Ribosomes as MachinesHow ribosomes influence which proteins are produced and when.(00:09:48) Ribosome RegulationThe regulatory layers within ribosomes and their possible variants.(00:14:35) Ribosomes and DiseaseHow ribosomal dysfunction is linked to a wide range of diseases.(00:18:16) Ribosome Mutations and DevelopmentCongenital disorders that can be attributed to specific ribosomal mutations.(00:20:44) RNA vs. Protein OutputWhy RNA measurements alone do not accurately predict protein levels.(00:24:16) Designing Ribosomes for TherapyThe potential of using engineered ribosomes for target therapies.(00:26:16) Small-Molecule Ribosome ModulatorsScreening compounds that may enhance ribosome activity for treatments.(00:28:39) Future Ribosome ProfilingIsolating individual ribosomes to understand their specific roles.(00:30:35) Future In a MinuteRapid-fire Q&A: scientific progress, community, and alternative career interest.(00:34:01) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Click Here,Text Us,Get a Shout-Out next episode.This Episode recorded and rendered on Reaper DAW.Hit play on a cozy, candid ride through creative tinkering, 80s nostalgia, and the kind of gratitude that only grows after a hard season. We start in the studio where we stress-test a new workflow, recording in Reaper and Audacity at the same time to chase better sound without risking the show. That practical look at tools and trade-offs opens into a broader conversation about making independent media in a value-for-value world—keeping the feed free, leaning on community, and learning in public.From there we move to the table—Thanksgiving memories, a second quiet dinner at home, and a cat that insists on a cameo. Music threads it all together. We found WSQK, a Stranger Things–themed internet radio station that spins 80s tracks and sly story nods, and it turned into an all-day soundtrack. The nostalgia isn't just fun; it's a mood shaper. That sets up a timely dive into why singing helps your health, pulling from BBC reporting on reduced stress, steadier heart rate, group bonding, and the simple joy of joining in rather than just listening.We also chew on a science headline: the oldest sequenced RNA from a woolly mammoth calf frozen in Siberian permafrost. It's a fascinating claim that deserves both curiosity and caution, so we unpack what RNA can reveal, what speculation might overreach, and how to love science without surrendering our questions. The emotional center lands in a personal story of recovery after a 2019 stroke—losing speech, movement, everyday skills—and the slow return of strength through prayer, rehab, family, and time. Gratitude shifts from a holiday word to a lived practice, and that's the heartbeat carrying us forward.Want to be part of the flock? Share a thought, send a voicemail, or drop us a line. If this conversation moved you, follow, share with a friend, and leave a review so others can find the show. Your support—prayers, talent, or a few dollars—keeps the mics on and the stories coming.Support the show I hope you enjoy the show! We believe in Value4Value for the podcaster and the listener alike. If you find value in our show, Please tell a friend or two. Word of mouth is the best way for our podcast to grow. If you haven't already, hit the "Follow" button. If you feel lead to, click on the support link and give financially. Say a prayer for us. Most importantly, please come back!Supporting us in anyway is much appreciated.Thanks for stopping by. Until Next time.73 and may the Father's love go with you.Bruce Email: theuglyquackingduck@gmail.comInstagram: https://www.instagram.com/theuglyquackingduck TikTok: https://www.tiktok.com/@theuglyquackingduck Facebook: The Ugly Quacking Duck Podcast Website: https://theuglyquackingduck.com
Click Here,Text Us,Get a Shout-Out next episode.This Episode recorded and rendered on Reaper DAW.Hit play on a cozy, candid ride through creative tinkering, 80s nostalgia, and the kind of gratitude that only grows after a hard season. We start in the studio where we stress-test a new workflow, recording in Reaper and Audacity at the same time to chase better sound without risking the show. That practical look at tools and trade-offs opens into a broader conversation about making independent media in a value-for-value world—keeping the feed free, leaning on community, and learning in public.From there we move to the table—Thanksgiving memories, a second quiet dinner at home, and a cat that insists on a cameo. Music threads it all together. We found WSQK, a Stranger Things–themed internet radio station that spins 80s tracks and sly story nods, and it turned into an all-day soundtrack. The nostalgia isn't just fun; it's a mood shaper. That sets up a timely dive into why singing helps your health, pulling from BBC reporting on reduced stress, steadier heart rate, group bonding, and the simple joy of joining in rather than just listening.We also chew on a science headline: the oldest sequenced RNA from a woolly mammoth calf frozen in Siberian permafrost. It's a fascinating claim that deserves both curiosity and caution, so we unpack what RNA can reveal, what speculation might overreach, and how to love science without surrendering our questions. The emotional center lands in a personal story of recovery after a 2019 stroke—losing speech, movement, everyday skills—and the slow return of strength through prayer, rehab, family, and time. Gratitude shifts from a holiday word to a lived practice, and that's the heartbeat carrying us forward.Want to be part of the flock? Share a thought, send a voicemail, or drop us a line. If this conversation moved you, follow, share with a friend, and leave a review so others can find the show. Your support—prayers, talent, or a few dollars—keeps the mics on and the stories coming.Support the show I hope you enjoy the show! We believe in Value4Value for the podcaster and the listener alike. If you find value in our show, Please tell a friend or two. Word of mouth is the best way for our podcast to grow. If you haven't already, hit the "Follow" button. If you feel lead to, click on the support link and give financially. Say a prayer for us. Most importantly, please come back!Supporting us in anyway is much appreciated.Thanks for stopping by. Until Next time.73 and may the Father's love go with you.Bruce Email: theuglyquackingduck@gmail.comInstagram: https://www.instagram.com/theuglyquackingduck TikTok: https://www.tiktok.com/@theuglyquackingduck Facebook: The Ugly Quacking Duck Podcast Website: https://theuglyquackingduck.com
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology." "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Download the transcript here
Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology." "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Listen to the podcast here
In this highly insightful episode of The Future Conceived, host Cam Schmidt talks with Dr. Carmen Williams, Senior Investigator at the National Institute of Environmental Health Sciences and the 2025 winner of the SSR Research Award.Dr. Williams, whose lab investigates the critical events of fertilization, shares groundbreaking findings on calcium signaling during egg activation. You will learn:Why the simple components of in vitro culture media, specifically calcium and magnesium ratios, dramatically control the frequency of calcium oscillations and influence the quality and development of the resulting embryo.New, compelling evidence linking these early calcium signals to metabolism (TCA cycle) and ribosomal RNA synthesis in the early embryo.The continued importance of research into endocrine disruptors, particularly plant estrogens, and their impact on reproductive tract differentiation.Dr. Williams also discusses her journey from electrical engineering to clinical medicine to basic science, and closes with a powerful message acknowledging the essential role of trainees in driving scientific success.
You don't have to understand every medical term to receive a miracle. In this powerful healing prayer session, Kathy leads you to target DNA, RNA, proteins, and prions so you can contend for full manifestation of your healing in Christ. Purchase Kathy's book Healed at Last – Overcome Sickness to Receive your Physical Healing on Amazon https://a.co/d/6a6mt8w or at: https://www.kathydegrawministries.org/healed-at-last/ Purchase Anointing Oil with a prayer cloth that Kathy has personally mixed and prayed over on Kathy's Website or Amazon. Order anointing oil by Kathy on Amazon look for her brand here https://amzn.to/3PC6l3R or Kathy DeGraw Ministries https://www.kathydegrawministries.org/product-category/oils/ Training, Mentorship and Deliverance! Personal coaching, deliverance, ecourses, training for ministry, and mentorships! https://www.kathydegrawministries.org/training/# In this prophetic healing and deliverance message, Kathy DeGraw equips you to pray at a deeper, more specific level over your body for radical breakthrough. Instead of just saying "rash go" or "sickness leave," you will learn to command every cell, chromosome, and protein to align with the perfect DNA and RNA God designed before the foundation of the world. Kathy releases targeted declarations over 125 trillion cells, T-cells, prions, the nervous system, immune system, gastrointestinal system, and especially neurodegenerative disorders such as dementia, Parkinson's, Alzheimer's, ADHD, and brain damage from trauma or birth defects. As you stand in the gap for yourself and your loved ones, you will renounce generational curses, break familiar spirits, and decree divine regeneration over your bloodline. If you are hungry to see what medical science says is impossible bow to the name of Jesus, this episode will train you how to pray, decree, and receive supernatural healing at the cellular level. #healingprayer #DNAhealing #neurologicalhealing #cellularrestoration #propheticspiritualwarfare **Connect with Us** - Website: https://www.kathydegrawministries.org/ - Facebook: https://www.facebook.com/kathydegraw/ - Instagram: https://www.instagram.com/kathydegraw/ Podcast - Subscribe to our YouTube channel and listen to Kathy's Podcast called Prophetic Spiritual Warfare, or on Spotify at https://open.spotify.com/show/3mYPPkP28xqcTzdeoucJZu or Apple podcasts at https://podcasts.apple.com/us/podcast/prophetic-spiritual-warfare/id1474710499 **Recommended Resources:** - Receive a free prayer pdf on Warfare Prayer Declarations at https://kathydegrawministries.org/declarations-download - Kathy's training, mentoring and ecourses on Spiritual Warfare, Deliverance and the Prophetic: https://training.kathydegrawministries.org/ - Healed At Last ~ Overcome Sickness and Receive your Physical Healing: https://www.kathydegrawministries.org/healed-at-last/ - Mind Battles – Root Out Mental Triggers to Release Peace!: https://www.kathydegrawministries.org/product/mind-battles-pre-order-available-january-2023/ -Kathy has several books available on Amazon or kathydegrawministries.org **Support Kathy DeGraw Ministries:** - Give a one-time love offering or consider partnering with us for $15, $35, $75 or any amount! Every dollar helps us help others! - Website: https://www.kathydegrawministries.org/donate/ - CashApp $KDMGLORY - Venmo @KD-Ministries - Paypal.me/KDeGrawMinistries or donate to email admin@degrawministries.org - Mail a check to: Kathy DeGraw Ministries ~ PO Box 65 ~ Grandville MI 49468
Since the late 19th century, the concept of an "alien invasion" has been a recurring theme in literature, and also served as a kind of cultural pressure gauge—it reveals our fears about what might be lurking in the cosmos, as well as the everyday horrors of the human condition, forcing us to confront questions about our vulnerabilities, and our assumptions about intelligent life elsewhere in the universe. This week on The Micah Hanks Program, we lead off with a bit of discussion about the persistent rumors about the interstellar comet 3I/ATLAS, and whether its presence could actually bring the discussion about alien visitation out of fiction and into reality. Then, we shift our attention to the discussion about what a real alien invasion might entail, and what it could mean for life on Earth if it were ever to occur; would humanity be up to the task of defending against a cosmic threat from beyond the stars? Have you had a UFO/UAP sighting? Please consider reporting your sighting to the UAP Sightings Reporting System, a public resource for information about sightings of aerial phenomena. The story doesn't end here... become an X Subscriber and get access to even more weekly content and monthly specials. Want to advertise/sponsor The Micah Hanks Program? We have partnered with the AdvertiseCast to handle our advertising/sponsorship requests. If you would like to advertise with The Micah Hanks Program, all you have to do is click the link below to get started: AdvertiseCast: Advertise with The Micah Hanks Program Show Notes Below are links to stories and other content featured in this episode: NEWS: Grandest Thanksgiving Yet? 2025 Holiday To Cost Average American Up To $1,000 Pranksters bypass Louvre's security and sneak painting in Oldest sequenced RNA reveals details about a mammoth's final moments 40,000 years ago Archaeological breakthrough contradicts the timeline of human civilization 3I/ATLAS: The Harvard Scientist, Kim Kardashian and the Comet That Probably Isn't an Alien Spaceship INVADERS: Increased UFO Reports Aren't Aliens, But Earth Is Still Unprepared for an Alien Invasion Aliens may have stopped trying to contact humans because they simply got bored, Nasa scientist claims Mind of its own: Will "general AI" be like an alien invasion? BECOME AN X SUBSCRIBER AND GET EVEN MORE GREAT PODCASTS AND MONTHLY SPECIALS FROM MICAH HANKS. Sign up today and get access to the entire back catalog of The Micah Hanks Program, as well as "classic" episodes, weekly "additional editions" of the subscriber-only X Podcast, the monthly Enigmas specials, and much more. Like us on Facebook Follow @MicahHanks on X. Keep up with Micah and his work at micahhanks.com.
From the mind of Vince Gilligan (Breaking Bad, Better Call Saul) comes the most original sci-fi premiere in years. In Episodes 1 & 2 of Pluribus (“We Is Us” and “Pirate Lady”), a rogue radio signal from deep space triggers a global transformation — and only one person is left unconnected: speculative romance author Carol Sturka, played by a powerhouse Rhea Seehorn.Brandon & Chanel dive into everything you missed:The alien RNA signal that infects the world via… saliva and donutsRhea Seehorn's brilliant performance as the reluctant resistanceThe arrival of Pirate Lady, a real-life version of Carol's book characterHelen's tragic death and what it means to “join” the hivemindSeizures triggered by Carol's emotions (that may have killed 11 million people
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the six biggest stories in biohacking and health tech, from sleep hormones to mitochondrial rejuvenation, giving you the data you need to live longer, think faster, and perform at your peak. This episode covers: • The Melatonin Heart Warning Everyone Missed A major new study from the American Heart Association reveals that long-term melatonin users face nearly twice the risk of heart failure and 3.5 times higher hospitalization rates. Once considered a harmless sleep aid, melatonin's hormonal effects may disrupt cardiovascular recovery, testosterone, and blood pressure regulation when used nightly. The takeaway: melatonin is a short-term circadian reset tool, not a forever supplement. Source: American Heart Association — newsroom.heart.org/news/long-term-use-of-melatonin-supplements-to-support-sleep-may-have-negative-health-effects • Bryan Johnson's Extreme Microplastics Detox Biohacker Bryan Johnson shared lab-verified results showing an 85% reduction in microplastics in his semen after one year of daily 200°F dry saunas followed by ice packs on the groin. It's not peer reviewed yet, but it'ssparking global discussion about environmental toxins, fertility, and detoxification. Whether or not you follow his protocol, this study highlights how widespread microplastics have become and how heat, sweat, and smarter exposure control may help fight back. Source: New York Post — nypost.com/2025/10/23/health/biohacker-bryan-johnson-got-rid-of-85-of-microplastics-from-his-semen • Urolithin A: The Mitochondrial Molecule That Strengthens Immunity A peer-reviewed human trial published in Nature Aging found that four weeks of daily Urolithin A (Mitopure®) supplementation improved immune function in adults aged 45–70, increasing youthful CD8 T-cells, natural killer cells, and mitochondrial performance inside immune cells. By triggering mitophagy, your body's cleanup process for old mitochondria, Urolithin A enhances energy, resilience, and immune strength. It's the clearest evidence yet that we can modulate immune aging through mitochondrial renewal. Head to timeline.com/dave to get 10% off your first order. Source: BioSpace — biospace.com/press-releases/timeline-continues-to-build-the-most-clinically-researched-longevity-products-targeting-immune-brain-and-muscle-aging • Google's New AI Model That “Talks” to Cells Google DeepMind and Yale launched Cell2Sentence-Scale, an open-source AI model that lets scientists query cellular pathways in natural language. The system can predict how cells transition from healthy to cancerous states and identify molecular switches that might reverse those changes. It's compressing years of biology into days and democratizing research for small labs and independent scientists alike. Isn't AI a beautiful thing? Source: Google DeepMind — blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery • Omega-3s Calm the Brain and the Temper A massive new meta-analysis of randomized controlled trials shows omega-3 fatty acids (EPA and DHA) reduce aggression by up to 28%. That includes both reactive anger and planned aggression. By lowering neuroinflammation and stabilizing cell membranes, omega-3s appear to balance dopamine and serotonin, proving that healthy fats aren't just heart food, they're emotional regulators too. Source: Science Alert — sciencealert.com/one-dietary-supplement-was-shown-to-reduce-aggression-by-up-to-28 • Chronic Fatigue Syndrome Finally Gets a Biomarker For the first time, researchers have developed a blood test that accurately identifies chronic fatigue syndrome (ME/CFS) using DNA methylation and micro-RNA expression patterns. This breakthrough distinguishes CFS from other autoimmune and viral conditions, marking a turning point for millions of patients long dismissed by traditional medicine. It's proof that data-driven diagnostics can transform how we understand mystery illnesses. Source: Science Daily — sciencedaily.com/releases/2025/11/251102205021.htm All source links provided for easy reference to the original reporting and research above. This is essential listening for fans of biohacking, hacking human performance, functional medicine, and longevity who want actionable tools from Host Dave Asprey and a guest who embodies what it means to age with energy, clarity, and vitality. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: melatonin heart risk, sleep hormones, microplastics detox, Bryan Johnson, Urolithin A, mitophagy, mitochondrial health, immune aging, DeepMind AI, cellular modeling, omega-3 aggression, neuroinflammation, chronic fatigue biomarker, ME/CFS test, biohacking news, longevity research Thank you to our sponsors! -LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser.-Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:18 — Story 1: Melatonin & Heart Health 1:58 — Story 2: Microplastics Detox 3:39 — Story 3: Urolithin A & Immune Function 5:19 — Story 4: AI Cell Model 6:57 — Story 5: Omega-3 & Aggression 8:43 — Story 6: CFS Blood Test 9:59 — Weekly Upgrade Protocol See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Broadcast from KSQD, Santa Cruz on 10-30-2025: Dr. Dawn opens with Halloween-themed scary medical stories, beginning with food toxins lurking in refrigerators and pantries. She explains how molds on grains and nuts, particularly Aspergillus species, produce aflatoxins that bind to DNA and cause liver cancer, making peanuts especially risky. Fusarium on wheat produces trichothecenes and fumonisins damaging cell membranes. Penicillium molds on fruits like apples produce patulin creating reactive oxygen species that harm organs. She advises discarding soft moldy foods entirely since fungal hyphae penetrate deeply, while hard cheeses can have moldy portions cut away. Meat spoilage involves bacteria producing cadaverine and putrescine, with E. coli, Campylobacter, Salmonella, and Clostridium causing severe illness through heat-stable toxins. A caller asks about yogurt-covered peanuts tasting rancid and confirms Botox contains botulinum toxin A in different salt forms, used medically for migraines, hyperhidrosis, and strabismus. The caller also describes paper-thin skin on sun-exposed forearms that bleeds easily. Dr. Dawn explains UV radiation damages collagen and elastin, making blood vessels vulnerable to shear forces. She recommends topical vitamin K products like Dermal K and protective lycra sleeves or gardening gauntlets to prevent injuries, emphasizing the need for annual dermatologic exams after extensive sun exposure. An emailer asks about RSV vaccine recommendations before overseas travel. Dr. Dawn disagreed with the couple's physician, citing US Preventive Services Task Force guidelines recommending RSV vaccination for all adults 60 and older, plus those 50+ with chronic conditions. She discusses FDA-approved home testing options including the PIXEL by LabCorp test for COVID, flu, and RSV, and iHealth rapid tests. She notes RSV point-of-care tests are available to medical practitioners and recommends thorough vaccination before international trips. Dr. Dawn presents a frightening investigation into private equity hospital bankruptcies, focusing on Steward Healthcare's 31 hospitals and Prospect's 16 facilities. Private equity firm Cerberus earned $700 million while Steward 650 documented incidents of deficient care including deaths. One woman died from hemorrhage after vendors repossessed equipment due to unpaid bills. She explains the shell game where companies sell hospital land to Medical Properties Trust, forcing new operators to pay rent while private equity extracts profits. The Brookings Institution study reveals systematic prioritization of investor returns over patient care, with courts failing to prevent these practices despite some states passing protective legislation. She discusses stillbirth rates being significantly underreported, with Harvard research showing actual rates of 1 in 147 pregnancies versus CDC's 1 in 175, worsening to 1 in 95 for black families. Over 70% involved known risks like obesity or diabetes, but 30% had no identifiable factors. Dr. Dawn emphasizes unconscious bias in medicine where women's complaints are dismissed, particularly affecting women of color and non-English speakers, noting both patient and provider biases require training to address. Dr. Dawn warns about HPV-related oral squamous cell carcinoma in young men, explaining that changing sexual practices over 30 years have created new transmission routes from genitals to mouth. Major risk factors include smokeless tobacco and hard alcohol which damage DNA. She mentions newly available saliva tests for persistent HPV detection, recommending risk factor reduction for positive cases. She concludes optimistically with a breakthrough Huntington's disease treatment using microRNA molecule AMT-130 delivered via virus to brain striatum. The treatment mirrors toxic Huntington protein's RNA, creating double-stranded structures cells destroy, preventing toxic protein accumulation. The three-year trial of 29 patients showed 75% slowing of disease progression with few side effects, offering hope for 100,000 Americans carrying the mutation, including 40,000 with current symptoms.
00:47 How bowhead whales live so longResearchers have uncovered a protein that enhances DNA repair and may explain how bowhead whales can live more than 200 years. The protein, cold-induced RNA-binding protein, was shown to enhance repair of double stranded DNA breaks, a particularly troublesome kind of damage. The team showed that this protein could also extend the lives of Drosophila flies and enhance repair in human cells. More needs to be understood about how this protein works, but the researchers hope that it could, one day, help prevent cancer and ageing in humans.Research Article: Firsanov et al.News: This whale lives for centuries: its secret could help to extend human lifespan11:22 Research HighlightsA precise way to grow crystals, with lasers — plus, the specialist organ that allows stinkbugs to protect their eggs from wasps.Research Highlight: How to grow crystals when and where you want themResearch Highlight: Stinkbug ‘ear' actually hosts parasite-fighting fungi13:31 An antivenom against a broad range of snakebitesResearchers have used ‘nanobodies' to create an antivenom that works against 17 snake species' venom. Snakebites kill millions each year, so getting the right antivenom can be life or death. But they are difficult to produce and often are very specific. Now, using nanobodies from llamas, researchers created an antivenom against a broad range of snake species' venom. The new antivenom can now even be produced without the llamas, and the team hope it will pave the way for a more universal antivenom.Research Article: Ahmadi et al.Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
Varroa mites remain the most destructive pest facing honey bees today—but a revolutionary new treatment may finally shift the balance. In this episode, Jeff Ott and Dr. Becky Masterman welcome Adam Pachl, North American Technical Manager for Bee Health at GreenLight Biosciences, to discuss Norroa, the first EPA-approved dsRNA-based treatment for Varroa mites. Norroa introduces a fundamentally new approach: instead of killing mites outright, it prevents them from reproducing. Adam explains how this RNA interference (RNAi) technology works at the molecular level, blocking the mites' ability to lay viable eggs without harming honey bees or other organisms. He also shares insights from years of field research, including trials across five U.S. states that demonstrated dramatic improvements in colony survival and mite suppression. Becky and Jeff explore the implications of this technology for beekeepers of all scales—from hobbyists managing a few hives to large-scale commercial operations—and how Norroa fits into an integrated pest management strategy. The discussion covers everything from timing of application, compatibility with other treatments, and safety testing, to potential future uses of RNAi against pests like Tropilaelaps. For the first time in decades, beekeepers may have a tool that targets Varroa precisely and safely—without collateral damage to the bees they're fighting to protect. Websites from the episode and others we recommend: GreenLight Biosciences. “GreenLight Biosciences Launches Norroa, the First RNA-Based Treatment for Varroa Mites.” 25 Sep 2025. https://www.greenlightbiosciences.com/articles/greenlight-biosciences-launches-norroa-the-first-rna-based-treatment-for-varroa-mites GreenLight Biosciences. “In the Pipeline: Protecting the Honeybee.” https://www.greenlightbiosciences.com/in-the-pipeline-protecting-the-honeybee GeneOnline. “EPA Registers Norroa as First RNA-Based Treatment for Varroa Mites Threatening Honeybee Populations.” 25 Sept 2025. https://www.geneonline.com/epa-registers-norroa-as-first-rna-based-treatment-for-varroa-mites-threatening-honeybee-populations Honey Bee Obscura Podcast: https://honeybeeobscura.com Project Apis m. (PAm): https://www.projectapism.org Honey Bee Health Coalition: https://honeybeehealthcoalition.org The National Honey Board: https://honey.com Honey Bee Obscura Podcast: https://honeybeeobscura.com Copyright © 2025 by Growing Planet Media, LLC ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com This episode is brought to you by Global Patties! Global offers a variety of standard and custom patties. Visit them today at http://globalpatties.com and let them know you appreciate them sponsoring this episode! Thanks to Bee Smart Designs as a sponsor of this podcast! Bee Smart Designs is the creator of innovative, modular and interchangeable hive systems made in the USA using recycled and American sourced materials. Bee Smart Designs - Simply better beekeeping for the modern beekeeper. Give your bees a boost with HiveAlive! Proven to increase bee health, honey yield, and overwinter survival, HiveAlive's unique formula includes seaweed, thyme, and lemongrass, making it easy to feed. Choose from HiveAlive's Fondant Patties, High-Performance Pollen Patties, or EZ Feed Super Syrup—ready-to-use options for busy beekeepers. Buy locally or online. HiveIQ is revolutionizing the way beekeepers manage their colonies with innovative, insulated hive systems designed for maximum colony health and efficiency. Their hives maintain stable temperatures year-round, reduce stress on the bees, and are built to last using durable, lightweight materials. Whether you're managing two hives or two hundred, HiveIQ's smart design helps your bees thrive while saving you time and effort. Learn more at HiveIQ.com. Thanks to Strong Microbials for their support of Beekeeping Today Podcast. Find out more about their line of probiotics in our Season 3, Episode 12 episode and from their website: https://www.strongmicrobials.com Thanks for Northern Bee Books for their support. Northern Bee Books is the publisher of bee books available worldwide from their website or from Amazon and bookstores everywhere. They are also the publishers of The Beekeepers Quarterly and Natural Bee Husbandry. _______________ We hope you enjoy this podcast and welcome your questions and comments in the show notes of this episode or: questions@beekeepingtodaypodcast.com Thank you for listening! Podcast music: Be Strong by Young Presidents; Epilogue by Musicalman; Faraday by BeGun; Walking in Paris by Studio Le Bus; A Fresh New Start by Pete Morse; Wedding Day by Boomer; Christmas Avenue by Immersive Music; Red Jack Blues by Daniel Hart; Original guitar background instrumental by Jeff Ott. Beekeeping Today Podcast is an audio production of Growing Planet Media, LLC ** As an Amazon Associate, we may earn a commission from qualifying purchases Copyright © 2025 by Growing Planet Media, LLC
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the five biggest stories in biohacking and health-tech — from genetic rejuvenation to your future digital twin — giving you the tools to live longer, perform better, and stay ahead of the curve.This episode covers:• Vitamin D as the Surprising “Anti-Aging Pill”A new five-year randomized study shows that daily 2,000 IU vitamin D supplementation slowed telomere shortening by 140 base pairs compared to placebo, translating to measurable gains in biological youth. Vitamin D isn't just for bones anymore — it's a foundational longevity molecule.Source: Science Daily — https://www.sciencedaily.com/releases/2025/10/251022023132.htm• The Supercentenarian Gene That Rejuvenates Old HeartsResearchers at the University of Bristol identified a gene variant, LAV-BPIFB4, common among people living past 100, that reversed cardiac aging in animal studies — restoring blood flow, heart strength, and tissue repair with a single treatment. It's a glimpse into how gene therapy could soon democratize superhuman longevity.Source: University of Bristol News — https://www.bristol.ac.uk/news/2025/october/progeria.html• FDA Closes the “GRAS” Loophole — Supplements Enter a New EraThe FDA just ended decades of self-certification for new dietary ingredients, requiring full agency review for anything entering the market. It's the biggest shakeup in supplement regulation in years — raising quality, accountability, and trust across the entire industry.Source: Mintz FDA Flux Newsletter — https://www.mintz.com/insights-center/viewpoints/2791/2025-10-16-fda-flux-october-2025-newsletter• Microbes That Trigger Autophagy — Your Gut as an Anti-Aging SwitchScientists at the University of Basel discovered that certain dietary bacteria containing double-stranded RNA can directly trigger autophagy, the body's built-in cell-recycling system. Fermented foods like kimchi, kefir, and sauerkraut may now be proven longevity tools for activating repair from the inside out.Source: University of Basel — https://www.unibas.ch/en/News-Events/News/Uni-Research/Longevity-research—Dietary-stress-supports-healthy-aging.htmlFurther reading: Neuroscience News — https://neurosciencenews.com/dietary-rna-cellular-aging-29757/• Your Medical Avatar Is Coming — The Digital Twin of YouForbes reports on the rise of personalized “medical avatars” — AI-powered digital twins built from your wearables and biometrics that can predict health risks, recommend interventions, and evolve alongside your biology. Doctors like Daniel Kraft call it generative health — a revolution in predictive medicine where your data literally becomes your doctor.Source: Forbes Innovation — https://www.forbes.com/sites/johnwerner/2025/10/21/wearables-ai-and-your-personal-medical-avatar/This is essential listening for fans of biohacking, human performance, functional medicine, and longevity sciencewho want real, actionable tools from Dave Asprey — the father of biohacking and founder of Bulletproof Coffee.With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your lifespan, and upgrade every system in your body and mind.New episodes drop every Tuesday, Thursday, Friday, and Sunday. Dave asks the questions no one else will — and gives you the science-backed tools to become stronger, smarter, and more resilient.Keywords: vitamin D longevity, telomeres, BPIFB4 gene, cardiac rejuvenation, supplement regulation, GRAS FDA, autophagy, microbiome, fermented foods, biohacking news, medical avatar, digital twin, predictive medicine, Daniel Kraft, quantum health, wearable AI, Dave Asprey, The Human UpgradeThank you to our sponsors! TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off.HeartMath | Go to https://www.heartmath.com/dave to save 15% off.Timestamps: 0:00 — Introduction0:18 — Story 1: Vitamin D & Telomeres1:02 — Story 2: Longevity Gene Therapy1:49 — Story 3: FDA Supplement Reform2:38 — Story 4: Gut Bacteria & Autophagy3:46 — Story 5: Medical Avatars4:53 — Weekly Protocol5:42 — OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2026 Ivy Podcast Discovery LLC
